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The early days of poliomyelitis: some historical notes
Sporadic cases of paralytic poliomyelitis have been reported for at least as long as
recorded history [62]. Despite its long history, however, poliomyelitis has had its most
notable effect on humanity within the past one hundred years. While the cumulative
number of poliomyelitis patients world-wide had reached an estimated 10 million
cases by the beginning of this century [79], no effective vaccine for this disease
existed before the 1950s and ignorance about the route of transmission often
hampered attempts to control its spread.
Poliomyelitis was, therefore, greatly feared, and the paralysis produced by this disease
(especially in the young) was a familiar sight during previous decades [62]. As
societies have improved their methods of sanitation (thereby eliminating a number of
diseases in the process) the likelihood has increased that individuals will be exposed
to poliovirus later rather than earlier in life, if at all. These p tterns of exposure have
resulted in a situation whereby this paralytic disease is no longer endemic in the
western world, but occurs instead in sporadic epidemics [102].
Today, thanks to increased levels of hygiene and vaccination, poliomyelitis is rare in
western countries. The cases that do occur are caused mainly by vaccine-associated
disease within countries that use the live attenuated vaccine, or by wild-type virus
infections within groups that refuse vaccination for religious reasons [5,61,74].
Poliomyelitis is also rapidly decreasing in most developing countries due to the World
Health Organisation’s vaccination campaigns [20].
Poliomyelitis presented a challenge to the scientific world for many years, as
scientists and epidemiologists struggled to understand the cause of this disease. The
first breakthrough occurred in 1909, when Dr. Karl Landsteiner discovered that
poliomyelitis was caused by a viral infection of unknown origin [62]. Dr. John F.
Enders, along with his colleagues Dr. Thomas Weller and Dr. Frederick Robbins, laid
the foundation for the development of poliovirus vaccines in 1949 when they
demonstrated the growth of poliovirus in cultures of non-neural cells [19]. Work by
other researchers using in vitro viral culture subsequently followed from this
important discovery, and Enders and his colleagues were rewarded for their work with
the Nobel Prize in 1954.
A second important discovery occurred in 1949, when investigators were able to
differentiate between the three different serotypes of poliovirus [6]. In 1952, Dr. Jonas
Salk succeeded in developing a formalin-inactivated poliovirus vaccine (IPV) and in
1955 this inactivated vaccine was approved for the vaccination of children against
poliomyelitis [82,83]. Vaccination campaigns in the USA and Europe soon followed,
with great success. In 1960, the live attenuated vaccine strains developed by Dr.
Albert Sabin were incorporated into a live attenuated oral vaccine (OPV) [81]. This
OPV vaccine, because of its low cost, ease of use, safe administration and
effectiveness against infection is now the vaccine of choice in the world-wide
vaccination campaigns run by the World Health Organisation (WHO) [20,103,104].
The structure of poliovirus
Polioviruses belong to the genus enterovirus within the family Picorn viridae. With a
diameter of 27-30 nm they are among the smallest viruses known, and contain a
single-stranded RNA molecule of positive polarity linked to a small protein at the 5’
region of the genome designated as the genomic virion protein (VPg). The entire
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nucleotide sequence has been determined and the total genome consists of 7440, 7440
and 7435 nucleotides for serotypes 1, 2 and 3 respectively [102]. The viral capsid
consists of 20 copies of each of the four structural virion proteins (VP1, VP2, VP3
and VP4) [40]. These viral capsid proteins protect the encapsidated nucleic acids from
degradation and interact with a specific cellular receptor on susceptible host cells: the
CD155 molecule [37].
Polioviruses can be classified into three distinct
serotypes based on their reaction to reference
panels of neutralising antisera [8]. Virus
neutralising antibodies against one of the three
serotypes do not protect against the other types,
although some cross-reactivity has been
described between the serotypes 1 and 2 [36,83].
The epitopes responsible for inducing poliovirus
neutralising antibodies are located at the end of
the loops on the three structural proteins: VP1,
VP2, and VP3 [18]. Because VP4 is located
entirely on the inside of the viral capsid, it plays
no known role in the induction of poliovirus-
neutralising antibodies. VP1 is the most exposed
surface protein and plays a major role in the
induction of neutralising antibodies for all three
poliovirus serotypes [94]. Three antigenic sites
(epitopes) involved in virus neutralisation have been identified on polioviruses based
on studies with Sabin-derived mutant viruses resistant to neutralisation by monoclonal
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Figure 1. Identified B and T cell epitopes on the structural proteins of poliovirus
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Monoclonal antibodies induced in mice have determined that antigenic site 1,
composed of amino acids 89 to 100 of VP1, is the major immunogenic site for
serotype 2 and 3 polioviruses [63]. This site is usually immunorecessive in serotype 1
[75]. Site 2 is a complex site combining residues 220 to 222 from VP1 (site 2a) with
residues including 169 and 170 and others on VP2 (site 2b) [63]. Both site 2a and 2b
have been detected in serotype 1 poliovirus, while only site 2b has been detected in
serotype 3 poliovirus. Site 3 is also a complex site and includes the residues 286 to
290 from VP1 (site 3a), and residues 58 and 59 from VP3 (site 3b). Both sites 3a and
3b have been detected in serotype 3 poliovirus, while as yet only site 3b has been
detected in serotype 1 poliovirus [75]. The immunological relevance of these three
antigenic sites in humans is not clear [Figure 1].
It is reported that trypsin, present in the intestinal fluids, can cleave both serotype 1
and serotype 3 polioviruses at antigenic site 1 at residue arginine-98 [26,45,80]. While
the virus in both cases retains its infectivity, the antigenic properties of the poliovirus
are drastically altered, and trypsin-cleaved viruses are not neutralised or
immunoprecipitated by monoclonal antibodies to site 1 of non-treated virions [45].
Pathogenesis of poliovirus infection
Polioviruses have a restricted host range and humans are the only reservoir of
naturally circulating poliovirus. Poliovirus can infect and cause flaccid paralysis in
chimpanzees and cynomolgus monkeys, but the remaining (wild) populations of these
animals are not large enough to sustain poliovirus circulation in the absence of human
infections [17]. In monkeys, paralysis is initiated most readily by direct inoculation
into the brain or spinal cord, and infection by the oral route is usually asymptomatic
[7,62]. Poliovirus is, however, excreted in the throat and stool after oral infection [86].
The incubation period of poliovirus is usually between seven and 14 days (range two
to 35 days) [62]. Poliovirus can be detected in the stool for five to six weeks following
infection and is present in the pharynx for one to two weeks after infection [1,41,62].
Transmission occurs mainly via the faecal-oral route and the virus can spread to other
people through contaminated water or food [1]. Survival of poliovirus in the
environment is highly variable, but viral inactivation is usually complete within
months [17] Following oral ingestion, poliovirus first multiplies in the pharynx and
the small intestine. After initial and continuing replication, probably in lymphoid
tissue of the pharynx and gut (Peyer’s patches), the virus is able to spread to other
lymph nodes until it is eventually detected in the bloodstream (viremia) [8,99].
Electron microscopy has demonstrated that poliovirus particles specifically adhere to
and are endocytosed by intestinal M-cells [87]. These data suggest that M-cells are the
site of poliovirus penetration of the intestinal epithelial barrier in humans.
Viremia can be detected as early as two to three days after infection. Once the virus
has reached the bloodstream, the anterior horn cells of the spinal cord are at risk for
infection unless sufficiently high levels of neutralising antibodies are present in the
circulation [7]. Not much is known about the manner in which polioviruses are able to
cross the blood brain barrier. Data from transgenic mouse experiments show that
polioviruses permeate through the blood brain barrier at a high rate, independently of
the poliovirus receptor [3]. It has also been proposed that polioviruses may cross the
blood brain barrier into the CNS via infected monocytes [39,25]. Meningitis or
paralysis can occur when neutralising antibodies are not able to block infection of the
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central nervous system. Inflammation occurs secondary to the infection of the nerve
cells; the infiltrations are mainly lymphocytes, with some polymorph nuclear cells and
plasma cells [7]. In addition to pathological changes in the nervous system,
hyperplasia and inflammatory lesions of lymph nodes, Peyer’s patches and other
lymph follicles in the intestinal tract are frequently observed [62]. Some degree of
recovery of motor functions may occur over the subsequent six months, but paralysis
still present at the end of this time remains permanent.
Most poliovirus infections (90-95%), however, do not result in clinical symptoms.
The infections that do become clinical can be divided into minor illness (4-8%) and
more severe illness (0.1-1%) such as paralysis or meningitis [53]. Minor illness (or
abortive poliomyelitis) is characterised by fever, malaise, sore throat, headache and
vomiting—all symptoms that can easily be mistaken as flu-like. Paralysis and
meningitis are relatively infrequent complications of poliomyelitis. The ratio of sub-
clinical to clinical infection in primary poliovirus infections does not in itself affect
the spread of wild type poliovirus but is important for an accurate assessment of the
extent to which the poliovirus has spread. This ratio varies according to serotype, and
is highest for serotype 3 (estimated at between 4000:1 and 500:1 [13,60,83]). The
lowest ratio is detected for serotype 1 (between 60:1 and 175:1 [60]) and intermediate
values are found for serotype 2 (1000:1 or higher [92]).
A sudden increase in muscle atrophy has been observed in 22% to 87% of persons
who have suffered from poliomyelitis, long after their apparent recovery  [12,11,53].
Remaining motor neurons take over the function of the lost neurons during the
recovery phases after acute poliomyelitis. Depending on the severity of the damage,
these remaining motor neurons have to innervate more than the usual amounts of
muscle fibres. This compensation mechanism can become exhausted during
subsequent years, leading to new symptoms of muscle weakness now known as post-
polio syndrome [11,12,53]. An alternative explanation suggested by some
investigators is that the reported presence of poliovirus-specific RNA in former
poliomyelitis patients indicates chronic viral infection [50,65].
Laboratory diagnosis of poliomyelitis
Cell culture isolation of poliovirus from the stool or pharynx early in the course of the
disease is diagnostic for poliomyelitis [104]. As the disease progresses, the detection
of the virus in the blood or cerebrospinal fluid (CSF) is also considered to be
diagnostic [62]. The WHO recommends that at least two stool samples should be
obtained from patients suspected of having poliomyelitis in order to increase the
probability of poliovirus isolation. These samples should be taken 24 hours apart as
early as possible in the course of the disease (ideally within the first 15 days after the
onset of disease) [104,105].
Polioviruses grow rapidly in cell culture, and cell destruction (cytopathic effect or
CPE) is usually complete within a few days [104]. The serotype of the isolate is
identified by virus neutralisation tests [104]. Intratypic strain differentiation is
necessary to determine whether the poliovirus isolate is wild or vaccine-related
[93,96]. An important benefit of virus isolation is that the molecular analysis of the
isolated viral genome can help to reveal the origin of the isolated poliovirus. The use
of molecular epidemiological methods has enhanced the precision and reliability of
poliovirus surveillance [47]. Poliovirus genomes evolve rapidly (~10-2 nt
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substitutions/genome/year) during replication in humans because of the lack of viral
RNA polymerase proof-reading during viral replication  [47]. Studies based upon
nucleotide sequence comparisons have revealed the existence of numerous genotypes
endemic in different regions of the world, enabling the study of transmission routes
[47].
The determination of the level of poliovirus-neutralising antibodies in serum is
considered to be the most specific assay for the estimation of protection against
poliovirus-induced disease. It is assumed that an antibody titer of 8 or higher is
sufficient for protection against the induction of paralysis, but it is not clear if persons
with lower titers are also protected [104]. Serological tests may be helpful in
supporting or ruling out a diagnosis of poliomyelitis if serum samples are obtained
early in the course of disease. However, the measurement of neutralising antibodies to
poliovirus for diagnostic purposes is not recommended by the WHO [104], due to the
fact that a) results are often difficult to interpret because antibody titers are similar in
vaccinated and infected persons, and b) neutralising antibodies appear early in the
course of infection, and seroconversion will have already taken place in many cases at
the time of the first clinical symptoms [62]. Determination of neutralising antibody
titers can, however, be helpful in assessing the level of protection against poliovirus
within a population.
Immunity to poliovirus after natural infection
Upon infection, poliovirus replicates in the epithelium of the pharyngeal and intestinal
mucosa and initiates a process that eventually results in mucosal immunity to
poliovirus [70]. Poliovirus-specific secretory antibodies are produced by plasma cells
originating in the gut-associated lymphoid tissues, mainly from the Peyer’s patches
[99]. The predominant class of immunoglobulin in the secretions of the alimentary
tract is secretory IgA, which engages in neutralising activity against poliovirus
[3,46,66,68]. The association between the presence of poliovirus-specific secretory
antibodies and protection against re-infection with poliovirus has been clearly
demonstrated [46,66-70]. Mucosal immunity provides a local barrier to poliovirus
infection, and therefore forms a first line of defense, preventing the pathogen from
entering the host [62,70,71]. Local immunity, however, is not absolute and can be
overcome by a sufficiently large dose of challenge virus [73]. The persistence of
poliovirus-specific secretory IgA has not been studied extensively. However,
poliovirus-specific secretory antibodies have been detected in nasopharyngeal
secretions 10-15 years after natural infection with wild serotype 1 poliovirus [70].
Following natural exposure, poliovirus-specific IgM and IgG appear in the serum
about 7-10 days after infection, and sufficiently high levels of these antibodies can
block poliovirus entry into the central nervous system [7]. The IgM response precedes
the IgG response, and peaks at about two weeks after the onset of disease,
disappearing from the serum within 60 days [66]. IgG levels increase steadily until
approximately eight weeks after infection. IgA antibodies appear in the serum two to
six weeks after exposure and remain at low levels [66].
It is generally believed that once a person has been naturally exposed to wild type
poliovirus they are protected for life from further disease induced by that specific
serotype [77]. The acquired immunity against re-infection, however, incomplete, as
was illustrated by Gelfand et al [29] in their investigation of households containing
General Introduction
 16
poliomyelitis patients in 1953-1955 (the beginning of the vaccination era). They
demonstrated that 20% of the persons with naturally acquired immunity were
undergoing a poliovirus infection [29]. Verlinde and Wilterdink [98] discovered in
1959 that excretion of poliovirus following challenge occurred in 31% of naturally-
immune children when OPV serotype 1 was used as a challenge virus, 37% when
serotype 2 was used, and 53% when serotype 3 was used.
Cell-mediated immunity to polioviruses in humans has been incompletely
investigated. Poliovirus-specific cell-mediated immunity as determined with
lymphocyte proliferation assays is seen in the early stages of acute poliomyelitis, but
disappears in most patients after three months [52]. Poliovirus-specific CD4-positive
cells (T-helper cells) could be found in the peripheral blood of participants in studies
where persons were immunised with live attenuated poliovirus vaccine [35,88].
Immune lymphocytes proliferate to polyacrylamide gel purified-capsid proteins VP1,
VP2 and VP3 and in some individuals, to synthetic VP4, indicating the presence of T
cell epitopes in each of these proteins [9,88] [Figure 1]. T cell epitopes adjacent to
each of the B cell antigenic sites in VP1 of poliovirus serotype 3 were identified. T
cell lines generated in response to poliovirus infection were cross-reactive between
the three serotypes. The response to the region adjacent to B cell antigenic site 1
(residues 97 to 114) was found to be immunodominant [33].
T cell clones induced in mice were found to be either serotype-specific or cross-
reactive between two or all three serotypes [55]. As in experiments conducted with
humans, the T cell clones recognised determinants on the surface capsid proteins VP1,
VP2, and VP3 and the internal capsid VP4 [Figure 1]. One serotype 3-specific T cell
clone recognised an epitope within amino acids 257 and 264 of VP1. Three T cell
epitopes corresponding to residues 14 to 28, 189 to 203, and 196 to 210 were
identified on VP3 of type 2 poliovirus. Four T cell epitopes were mapped to an
immunodominant region of VP4, encompassed within residues 6 and 35. The VP4
epitopes were conserved between serotypes. In contrast, T cell clones that recognised
epitopes on VP1 or VP3 were largely serotype specific.
The exact importance of T cell-mediated immunity to poliovirus and its role in
recovery, protection from re-infection and the destruction of nerve tissue is not
known. Neutralising antibodies are thought to be important for clearing poliovirus
infections because children with agammaglobulinemia get persistent infections [108].
However, it is not possible to cure these patients or clear the poliovirus from the CNS
even with the infusion of high titered antibody into the cerebrospinal fluid [59,78]. In
addition, poliovirus persistence has occurred in persons with pure T cell deficiencies
and normal immunoglobulin levels and antibody responses [34]. It would appear,
therefore, that T cells or other cellular immune mechanisms play at least a partial role
in the clearance of poliovirus from the CNS.
Vaccination against poliomyelitis
It goes without saying that both the development and the successful use of poliovirus
vaccines have exerted a major influence on the spread of poliovirus. The principal aim
of vaccination was originally to protect the vaccinated individual from disease. Within
the context of vaccination programmes for larger populations, vaccination is able to
enhance herd immunity to such an extent that the chain of transmission can be
inhibited or even interrupted within a given community or country [62]. Two different
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vaccines are currently used in vaccination campaigns against poliomyelitis: the
inactivated poliovirus vaccine (IPV) and the live attenuated poliovirus vaccine (OPV).
Dr Jonas Salk developed the first inactivated polio vaccine (IPV) using polioviruses
grown on monkey kidney cells that were subsequently formalin-inactivated [82].
After extensive field testing, IPV was licensed in the United States in 1955, using the
Mahoney (serotype 1), MEF-I (serotype 2) and Saukett (serotype 3) poliovirus strains
[82]. Dutch polio vaccination with IPV started in 1957, and IPV has been produced at
the RIVM in The Netherlands since 1959. Today, The Netherlands, Finland, Sweden,
France, Iceland, Norway and parts of Canada use this inactivated polio vaccine in
their national vaccination programs. The same strains are still used by all
manufacturers of IPV today with the exception of Sweden, where the Brunenders
strain is used for serotype 1 [83].
The original IPV, given intramuscularly, contained 20, 2, and 4 D antigen units of
poliovirus serotype 1, 2 and 3 respectively. In 1978, the RIVM introduced a new
culture technique using cells on microcarriers to produce a more potent IPV [95,97].
The IPV used today in The Netherlands contains 40, 4 and 7.5 D antigen units per
dose. A total of six IPV vaccinations are given at 3, 4, 5 and 12 months and 4 and 9
years of age. The enhanced IPV (eIPV) used in other countries contains 40, 8 and 32
D-antigenic units per dose of serotype 1, 2, and 3 respectively [62].
The antigenic site 1 of serotype 3 poliovirus is immunodominant [63] and
intramuscular vaccination with the complete inactivated virion will, in theory, mainly
induce antibodies to this antigenic site. Upon mucosal infection with wild-type
poliovirus, trypsin (which is present in the gastrointestinal tract) cleaves the antigenic
site 1 of serotype 3 poliovirus, leaving neutralising antibodies to this site useless
[26,45,80].  For this reason it has been suggested that IPV might be supplemented
with trypsin-cleaved serotype 3 poliovirus antigen in order to achieve a vaccine with
sufficiently broad immunogenicity [43].
The attenuated polioviruses used in the live vaccines are no longer neurovirulent and
rarely cause poliomyelitis (vaccine-associated poliomyelitis) [102]. This vaccine is
applied orally with the advantage that it replicates in the host, inducing local
immunity in the gut and at other mucosal sites. Further, the Sabin vaccine may
contribute to the immunisation of subsequent contacts because is spread faecally [62].
OPV-induced mucosal immunity is important because it is able to reduce the spread
of wild type polioviruses upon its (re)introduction into a population, thereby assisting
in the creation of sufficient herd immunity [62]. In 1991, the success of controlling
poliomyelitis in the Americas led the EPI Global advisory group to recommend, on a
global basis, the formulation of trivalent OPV with 106, 105 and 105.8 TCID50 per
dose of serotypes 1, 2 and 3, respectively [21]. The schedule recommended today is
one dose at birth and 3 doses of OPV at 6, 10 and 14 weeks of age.
There are some recognised problems with the distribution of OPV. Breaks in the cold-
chain in developing countries, for example, can lead to loss of vaccine effectiveness in
tropical countries [16]. Further, malnutrition and infection with other enteroviruses
are known to interfere with the effect of OPV vaccination [56]. The greatest
disadvantage of OPV, however, is the risk of back-mutation to neurovirulent strains
and the introduction of a wide variety of live mutant viruses into the population
[20,90,108]. However, the risk of vaccine-associated paralytic poliomyelitis (VAPP)
is low, with only one case reported for every 3.3 million doses of trivalent OPV that
are distributed [20,90,108]. Serotype 3 is most commonly associated with paralysis in
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vaccine recipients, while serotype 2 has primarily been associated with paralysis
among contacts of OPV recipients [20]. The risk for VAPP is highest following the
first dose of OPV (1:570,000) and among persons with primary B cell
immunodeficiencies [90,108]. Despite the risk of (OPV) vaccine-associated paralysis
this vaccine was chosen by the WHO because of its low cost, ease of use, safe
administration and effectiveness against infection.
Induction of systemic immunity by vaccination with IPV and OPV
Both the (e)IPV and the OPV vaccines are capable of inducing high levels of
circulating neutralising antibodies. However, vaccination with IPV has been described
as inducing high percentages of seroconversions with only one or two doses [4,64,76].
Vaccination with eIPV induces more than 90% seroconversion (titer ³8) against all
three types of poliovirus after only one dose and 100% seroconversion after two doses
[4]. In contrast, vaccination with OPV requires three or more doses to reach similar
levels of neutralising  antibodies in the serum.
The responses to trivalent OPV in tropical countries are generally lower than those
observed in the western world [16,56]. Accumulated data from 15 studies that have
examined the response to three doses of trivalent OPV in developing countries reveal
a wide variation in the number of children seroconverting, with rates ranging from
36% to 99% for serotype 1, 71% to 100% for serotype 2, and 40% to 99% for
serotype 3 [76]. Serological surveys carried out 15 years or more after the beginning
of national OPV coverage indicate at least 95% neutralising antibody seroprevalence
against all three serotypes of poliovirus in persons two years of age and older
[32,58,84]. The average number of seropositives and/or seroconversion is lowest for
serotype 3, followed by serotype 1 for both the OPV and IPV vaccine [62].
Induction of mucosal immunity by vaccination with IPV and OPV
Several studies have investigated mucosal immunity after vaccination with OPV and
IPV [see Table 1]. Most of these studies are limited in scope because they focus
mainly on serotype 1 poliovirus in young children shortly after immunisation [31,49].
In addition, they use different vaccine compositions (such as IPV, eIPV and different
OPV vaccines) and many different vaccination schedules. These factors make a
comparison of the various studies difficult. It should also be noted that some of these
studies were carried out shortly after the start of the vaccination era [15,46,81,100], in
areas where wild type poliovirus still circulated, or where OPV vaccination was
widely used [49,73]. It is impossible to exclude the effect of additional infection with
live poliovirus (vaccine or wild-type) under these circumstances.
The mucosal immune response to OPV closely parallels that of natural infection.
After the administration of OPV, the virus is expected to multiply in the same
alimentary tract sites and related lymphoid tissues and is shed in the stool for several
weeks [24]. Secretory IgA is induced in the nasopharynx and intestine approximately
one to three weeks after immunisation [66]. IgA can still be detected in the
nasopharynx at 60 to 100 days after vaccination [66]. The secretory IgA response
rapidly returns after revaccination, but usually for a shorter duration, although some
studies describe the persistence of secretory antibody activity for as long as five to six
years [71,89]. The poliovirus-specific IgA induced after OPV vaccination is also
found to be protective against poliovirus infection as demonstrated by several
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challenge experiments with OPV, and after natural exposure [31,38,72,73] [Table 1].
Protection from re-infection is incomplete and re-infection remains possible in about
one third of recipients [73].
One early study demonstrated that IPV vaccination was unable to induce a secretory
IgA response in the nasopharynx or in stool samples [46]. Other researchers later
demonstrated some induction of poliovirus specific IgA in the nasopharynx as well as
reduced viral shedding after vaccination with the new eIPV [15,22,28,38,81,89,109].
However, the induction of sIgA described in these studies was at lower levels (9%-
88%) than was the case after vaccination with OPV (26%-100%) [22,109].
Most studies show decreased pharyngeal shedding of poliovirus in IPV recipients
compared to non-immunised children [15,28,38,81]. The effect on reduced pharyngeal
shedding was highest in IPV vaccinated children with neutralisation titers of 8 or
higher [44,57]. Only 38% of these children excreted poliovirus from the pharynx. In
contrast, 75% of the group of children with titers below 8 shed poliovirus from the
pharynx [44]. Further analysis of the prevalence of wild-type poliovirus in household
contacts of patients revealed that poliovirus was less frequently isolated from the
nasopharynx in IPV recipients than in non-vaccinated children. [57,101]. In contrast,
these studies have not consistently demonstrated decreased faecal shedding of
poliovirus. A number of these studies [15,49] demonstrated a decrease in the duration
of excretion and the amount of poliovirus present in the stool in IPV recipients
compared with non-immunised children. Other studies, however, report no difference
[2,31,38,81].
Several researchers investigated poliovirus infection in IPV vaccinated household
contacts of patients with paralytic poliomyelitis during the first decade after the start
of IPV vaccination in the USA. All studies showed that there was no significant
difference between IPV-vaccinated and non-vaccinated children within the
households in the duration, amount and proportion of persons excreting wild type
poliovirus [14,23,42,57,100,101].
Gelfand et al [29] studied naturally-occurring poliovirus infection in IPV-vaccinated
families, and reported no significant difference in the pattern of transmission between
IPV-vaccinated and non-immunised family members within infected households.
However, among IPV-vaccinated persons with neutralising antibody titers of 128 or
higher, the duration of faecal shedding was shorter (although the proportion shedding
virus did not differ) than in persons with lower neutralising antibody titers in the
serum [57]. Several studies report a correlation between serum NT titers and a
reduced shedding of poliovirus from the stool and nasopharynx [15,44,51,57]. In most
of these cases, however, the possibility that part of the NT titers may have been
induced by additional infection with OPV or with wild-type poliovirus cannot be
excluded. Unfortunately, the NT test does not discriminate between antibodies that are
induced by inactivated versus live poliovirus.
In summary, studies that investigate mucosal immunity after IPV vaccination show
partly conflicting results with respect to the induction of IgA and differences in the
reduction of viral shedding after an OPV challenge [Table 1]. Nevertheless, it is clear
that all studies comparing responses of IPV- and OPV-immunised children show a far




Table 1. Summary of studies investigating mucosal immunity after IPV or OPV
vaccination.
Mucosal IgA induction :
% with poliovirus-specific IgA
Stool  Saliva Vaccine/Country
IPV OPV IPV OPV
Keller [46] 1968 0 nd 0 nd trivalent/Switzerland
Smith [89] 1986 nd nd 9* 26 trivalent/USA/Sweden
Zhaori [109]1988 nd nd 27* 70 type 1/USA
Faden [22] 1990 nd nd 41-88* 75-100 trivalent/USA
Viral shedding after OPV challenge :
% shedding challenge virus
Stool  Pharynx Challenge Virus/
Country
IPV OPV IPV OPV
Ghendon [31]1961 74 37 nd nd type 1/USA
Dick [15] 1961 63 nd 0 nd type 1/UK
Henry [38] 1966 83 32 nd nd type 1/UK
Onorato [73]1991 63* 25 1* 4 type 1/USA
Kok [49] 1992 7.1* 3.3 0* 0 type 1/Kenya
* = eIPV, nd = not determined
The problem remains that methodological differences between these studies often
result in data that are difficult to compare [15,46,81,100]. It is important to bear in
mind that additional mucosal priming can not be excluded in most of these cases.
Whether or not IPV alone is able to exert an effect on mucosal immunity is still
unclear from the results of these studies, and many different opinions currently
surround this topic.
Prospects for eradication of poliovirus
In 1988, the World Health Assembly decided to strive for the eradication of
poliomyelitis by the year 2000 [103]. The WHO estimates that current levels of
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immunisation coverage prevent some 550,000 cases of paralytic poliomyelitis each
year. The eradication of poliovirus will be considered complete when a) no more
cases of poliomyelitis caused by wild-type poliovirus occur, and b) poliovirus is no
longer circulating in humans (vaccinated or non-vaccinated) or in the environment
[104].
Figure 2. Wild Poliovirus in 1988
Figure 3. Wild Poliovirus in 1998
Methods of reaching this eradication goal include the implementation of a world-wide
vaccine coverage of 80% or more of all new-born children, along with high quality
clinical and environmental surveillance. Clinical surveillance recommended by the
WHO includes the virological investigation of all patients with acute flaccid paralysis
Known or probable wild
poliovirus transmission




(possible poliomyelitis cases) and their contacts [105]. Environmental surveillance
includes the detection of poliovirus in the environment (for example, sewage water).
The last cases of wild-type induced poliomyelitis in the United States were reported in
1979. Since then, apart from rare cases of imported poliomyelitis, all reported cases of
paralytic poliomyelitis in the United States have been vaccine-associated. The last
case of poliomyelitis caused by wild-type poliovirus in the rest of the Americas was
reported in August of 1991 in Peru. Despite improved surveillance, no other cases of
poliomyelitis caused by poliovirus have been detected in this region, and in
September 1994 the international Poliomyelitis Eradication Certification Committee
certified the Americas to be free of wild type poliovirus [103].
Many other regions are now on their way to becoming certified [106,107]. The main
problem areas for poliovirus circulation today are India and large parts of Africa—
developing countries in which routine immunisation alone may not be sufficient for
the interruption wild-type poliovirus transmission [106,107]. A set of national
immunisation days, at which time two doses of OPV one month apart are given to all
children under 5 years of age regardless of their immunisation status, may be more
effective in these regions. The use of OPV during national immunisation days in these
developing countries is either soon to be or has already been applied. This strategy has
proved to be very successful in China and in the Pacific region. Figures 2 and 3 show
the areas of known or probable wild poliovirus transmission in 1988 and 1998
respectively.
Outbreaks of poliomyelitis in The Netherlands and Finland
For the eradication program to succeed, transmission of wild-type poliovirus must
cease completely [104]. Important information pertaining to the influence of IPV and
OPV vaccination on the transmission of wild-type poliovirus can be obtained through
analysis of recent poliomyelitis outbreaks. Outbreaks of poliomyelitis in countries
using IPV or OPV have shown that epidemics can occur in areas that have been free
of poliomyelitis for several years [43,48,68,74,85,91]. Despite the good clinical
efficacy of both OPV and IPV and a high level of coverage, neither of these vaccines
has been able to completely break the transmission of poliovirus. This can be
concluded from the substantial proportion (between 21% and 39%) of fully vaccinated
persons (both OPV and IPV) that appear to be involved in the chain of wild-type
poliovirus transmission [43,48,68,74,85].
As previously noted, mucosal immunity is considered to be of particular importance
for protection against (re)infection with poliovirus, thereby interrupting the chain of
transmission of wild-type poliovirus [62,70,71]. IPV vaccination is thought to induce
little or no mucosal immunity against poliovirus. For this reason, outbreaks in
countries that use IPV exclusively in their vaccination programs are of special interest
for the study of the transmission of poliovirus. Recent outbreaks in The Netherlands
and in Finland are described below.
Between 1970 and 1980, the immunisation schedule in The Netherlands consisted of
five doses of IPV during childhood. Coverage with three or more doses was higher
than 95%. A type 1 epidemic with 110 notified cases (80 with paralysis) occurred in
1978 among non-immunised members of a religious group rejecting vaccination [85].
During this outbreak, 21% of fully immunised school children excreted wild type
poliovirus, while 46% of non-immunised children excreted the virus [85].
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Monovalent serotype 1 OPV vaccine was distributed among the risk groups to control
the outbreak, which eventually spread to non-immunised overseas contacts among
members of the religious group in Ontario (Canada) and the USA [27]. The
Netherlands changed to a schedule of 6 IPV doses following the 1978 outbreak,
attaining a level of coverage that exceeded 97%. The members of the religious group,
however, continued to refuse vaccination. In 1992, after 14 years without endemic
cases, a serotype 3 poliovirus outbreak occurred within this non-vaccinated group,
with a total number of 71 patients [74]. This outbreak was investigated at schools, in
the environment, at virus diagnostic laboratories and in the general population. No
spread to other parts of the country was observed during the outbreak [10].
Six doses of IPV are used in the Finnish vaccination schedule and the coverage has
been more than 90% for many years. An outbreak due to a serotype 3 poliovirus
occurred in 1984 [43]. Nine cases of poliomyelitis were identified, two of which had
received five doses of IPV in the past. Investigation of healthy contacts and other
healthy persons showed the serotype 3 poliovirus to be widespread, and at least
100,000 persons were estimated to have been infected. A significant factor
contributing to this outbreak was impaired herd immunity to the epidemic strain,
which differed from the serotype 3 vaccine strain. Wild-type isolates had alanine 99
substituted by valine, and arginine 98 replaced by either serine or asparagine in the
immunodominant region on VP1 [43]. In addition, the geometric mean titers of serum
samples were lower against the epidemic strain when compared to the titers against
the strains used to manufacture the inactivated vaccine, which also contributed to
lower vaccine efficacy [54].
Outline of this thesis
The last outbreak in The Netherlands (in 1992/1993) raised a number of questions,
such as whether the IPV vaccine provided sufficient protection against wild-type
serotype 3 poliovirus, and whether the IPV-vaccinated population in The Netherlands
was contributing to poliovirus circulation [30]. In this light, the induction of mucosal
immunity by IPV vaccination in The Netherlands is of special interest, since mucosal
immunity is considered to be of great importance for the interruption of transmission
and a reduction in spread of poliovirus within the population. The experiments
described in this thesis have been conducted to study the contribution of IPV
vaccination to immunity from and protection against infection with poliovirus. We
have developed new immunological tools for the rapid detection of poliovirus-specific
antibodies and for the investigation of the induction of mucosal immunity after IPV
vaccination.
An enzyme-linked immunosorbent assay-based Poliovirus-Binding Inhibition test to
detect and quantify antibodies to polioviruses has been optimised and evaluated for
use in population studies as an alternative to the virus neutralisation test in tissue
culture (Chapter 2).
Chapter 3 presents research examining differences in response to the antigenic sites 1
and 3 of serotype 3 poliovirus between previously OPV- and IPV-vaccinated persons,
to investigate possible gaps in the immune response to trypsin cleaved serotype 3
poliovirus induced by IPV vaccination.
An IgA ELISA was developed and evaluated in order to answer the question of
whether vaccination with IPV induced IgA. The seroprevalence of poliovirus-specific
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IgA in the circulation of poliomyelitis patients and in the general IPV-vaccinated
population of The Netherlands was investigated, as well as the IgA response to
poliovirus in naturally-exposed persons after a single dose of IPV. The results are
presented in Chapter 4.
The kinetics of the IgA response in serum and saliva after IPV booster vaccination in
previously OPV- and IPV- vaccinated subjects was studied to test the hypothesis that
IPV vaccination is able to induce mucosal poliovirus-specific IgA in persons who
have been previously primed with live poliovirus at mucosal sites. ELISA and
ELISPOT-assays were used for the detection of virus-specific IgA responses (Chapter
5).
New assays that enable the detection of poliovirus-specific antibodies or viral RNA
have been developed during the last decade. The 1992/1993 poliovirus type 3
outbreak in The Netherlands has provided an opportunity to examine the potential of
various methods for poliomyelitis diagnosis and their value in the eradication
program. The results of using these new methods and their implications for the future
diagnosis and clinical surveillance of poliomyelitis are described in Chapter 6.
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An enzyme-linked immunosorbent assay (ELISA)-based Poliovirus-Binding
Inhibition test (PoBI) to detect and quantify antibodies to polioviruses was optimised
and evaluated for use in population studies as an alternative to the virus neutralisation
test (NT) in tissue culture. The sensitivity of the inhibition ELISA as compared with
the NT in an inactivated poliovirus vaccine (IPV)-vaccinated population was 98.6%,
97.4% and 92.1% for serotypes 1, 2 and 3 respectively. The specificity of the PoBI
test, as determined with sera from non-vaccinated persons, was also high for all three
serotypes (99.0%, 95.8% and 100%). Antibodies to other enteroviruses did not cross-
react in the serotype 1 or the serotype 3 PoBI, and only low levels of cross-reactivity
were found for serotype 2. We found high correlations between the PoBI and NT
titers for serotypes 1 and 2 in IPV-vaccinated blood donors (0.97 and 0.95), in oral
poliovirus vaccine (OPV)-vaccinated blood donors (0.91 and 0.95) and in naturally
immune persons (0.90 and 0.87). The correlation coefficient for serotype 3, however,
was significantly lower in OPV-vaccinated blood donors (0.73) and in naturally
immune persons (0.76) than in IPV-vaccinated persons (0.94; p<0.01). These results
indicate that the antibody response to serotype 3 poliovirus in IPV-recipients is
different from that in OPV-recipients and naturally infected persons. We conclude
that the PoBI test is a suitable alternative for the NT to estimate the seroprevalence of
neutralising antibodies to poliovirus, especially in large scale population studies.
Introduction
Poliovirus neutralising antibodies in serum are sufficient for protection against
paralytic disease [2,4,12,16]. These neutralising antibodies, thought to be
predominantly of the IgG isotype, prevent poliovirus from reaching the central
nervous system [5,11]. The neutralisation test (NT) is used as the standard test for the
measurement of immunity to the three serotypes of poliovirus after vaccination or
natural exposure. Advantages of the NT are the high sensitivity, specificity and
acceptance of this assay. The NT has been chosen by the WHO as the reference
method for determining immunity against poliovirus [19]. However, the need to use
cell culture and the long duration of the test (up to six days) make the NT expensive
and less suitable for large scale screening of populations for protection against
poliomyelitis. In addition, in view of the probable eradication of poliovirus in the near
future, the use of live (wild-type) polioviruses in laboratory research and diagnostic
assays (such as NT) will be discouraged or prohibited, and alternative methods for the
immuno-surveillance of populations will be needed.
Recently Edevag et al. [1] described an inhibition-ELISA for the detection of
neutralising antibodies using inactivated polioviruses as antigen. With this inhibition-
ELISA (Poliovirus-Binding Inhibition assay; PoBI), a high correlation with the
standard neutralisation test was found with a small set of sera in a pilot study. The
specificity of the assay was not fully evaluated. Because the PoBI test is a promising
alternative for the NT, we have optimised and evaluated the assay for use as a
replacement of the NT in large scale population studies. In order to do so, we tested
sets of sera from 1] persons vaccinated with inactivated poliovirus vaccine (IPV) or
live attenuated oral poliovirus vaccine (OPV); 2] persons with documented infection
with poliovirus; 3] a known seronegative population; 4] rabbits, each immunised with
one of 41 different enteroviruses and 5] a cross-sectional epidemiological survey
aimed at the evaluation of the national vaccination program in the Dutch population.




The PoBI test was performed according to the method described by Edevag et al. [1]
with modifications, and was conducted in two steps. For the first step (pre-incubation
of serum and virus), microtiter cell culture plates (Greiner, Alphen aan den Rijn, The
Netherlands) were blocked with 150 µl of 0.5% bovine serum albumin (BSA) in
phosphate-buffered saline (PBS) for 1 h at 37°C. Two-fold dilutions of serum samples
were made directly into the wells (75 µl/well, 1:2 to 1:4,096) in dilution buffer (PBS
with 0.5% Tween 20, 0.5% BSA, 0.5 M NaCl). Monovalent, inactivated vaccine virus
produced at the National Institute of Public Health and the Environment (RIVM) was
used as antigen. The formalin-inactivated poliovirus was added to each well at
concentrations of 20, 4 and 16 D-antigen units/ml for serotypes 1, 2 and 3,
respectively, in a volume of 75 µl per well. The concentration of D-antigen was
quantified with a direct ELISA [18]. Poliovirus serotype 1 was Mahoney, serotype 2
was MEF, and serotype 3 was a Saukett strain. Serum-virus mixtures were incubated
for 2 h at 37°C.
For the second step, Maxisorp ELISA plates (Nunc, Roskilde, Denmark) were coated
with the IgG fraction of bovine antipoliovirus hyperimmune serum in dilutions of
1:500 for serotypes 1 and 2 and 1:250 for serotype 3 in 0.04 M carbonate-bicarbonate
buffer pH 9.6 (overnight at 4°C). Plates were blocked with 100 µl of  0.5% BSA in
PBS for 1 h at 37°C. After blocking, 100 µl of the pre-incubated serum-virus mixture
was transferred to the ELISA plate and incubated for 2 h at 37°C. For detection of
bound antigen, serotype-specific monoclonal antibodies—type 1 (14D2E9, 1:3,000),
type 2 (6-15C6, 1:10,000), and type 3 (2-13D9, 1:10,000)—in dilution buffer were
added for 1 h at 37°C [13]. The monoclonals used for serotype 1 were directed against
antigenic site 2a, while the monoclonals used for serotype 2 and 3 were directed
against antigenic site 1 of the corresponding poliovirus capsid. Goat anti-mouse IgG
alkaline phosphatase conjugate (Sigma, Zwijndrecht, The Netherlands) was
subsequently added in a dilution of 1:500 and incubated for 1 h at 37°C. The substrate
p-nitrophenylphosphate (Sigma) at a concentration of 1 mg/ml in 0.1 M glycine buffer
(pH 10.4) was incubated at room temperature for 30 min. Plates were read at 405 nm
by use of a Microwell System 510 spectrophotometer (Organon Teknica, Eindhoven,
The Netherlands).
For the evaluation of the PoBI test, serum samples were considered positive if a
reduction in extinction of ³50% was reached. The reciprocal of the first serum
dilution that was positive in the inhibition test was taken as the titer of the test sample.
A standard in-house reference serum with known titers was included in each assay.
Optimal dilutions of the coat, detector monoclonal antibodies, and conjugate were
established by checkerboard titrations.
Neutralisation test
Poliovirus neutralising antibody titers of sera were determined in the standard NT as
recommended by the World Health Organisation [19] by using the Mahoney (serotype
1), MEF (serotype 2), and Saukettt (serotype 3) virus strains as challenge viruses. In
brief, serial two-fold dilutions of sera to be tested and 100 50% cell culture infective
doses of virus were incubated in 96-microwell plates at 37°C for 3 h. After the
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incubation, 1.75 x 104 Hep-2C cells were added per well. The plates were read after
six days of incubation at 37°C. The titers are expressed as the reciprocal of the highest
dilution showing complete neutralisation of the cytopathic effect of 100 50% cell
culture infective doses. Samples were considered positive if NT titers were ³8 (log2
titer, 3).
Serum samples
For evaluation of the PoBI test, the following groups of sera were examined: 1] Sera
were obtained from IPV-vaccinated blood donors in The Netherlands (n=26) and from
OPV-vaccinated blood donors in Belgium (n=42). 2] Sera were obtained from a group
of non-vaccinated elderly persons (age 52 to 85 years) in The Netherlands that had
been given a single dose of IPV (n=47). This group was presumably naturally exposed
at a young age, when poliovirus was endemic in The Netherlands [8]. Sera were
collected at the time of IPV vaccination, and at one and four weeks thereafter. 3]
Negative-control sera were obtained from non-vaccinated children (n=96) from a
population that refuses vaccination for religious reasons. None of these serum samples
had detectable neutralising antibodies (titer, <2) against poliovirus. In addition, all
sera were also negative for antibodies to other components of the vaccine cocktail
(diphtheria and tetanus toxoid) that is used in the routine immunisation of children in
The Netherlands. 4] Serum samples were obtained from rabbits hyperimmunised with
either poliovirus serotype 1 (Brunhilde; NT titer: type 1, 20,480; type 2, 10; type 3,
<10), serotype 2 (MEF-1; NT titer: type 1, 10; type 2, 81,920; type 3, <10), or
serotype 3 (Saukett; NT titer: type 1, <10; type 2, <10; type 3, 40,960) or with other
enteroviruses (coxsackievirus B serotypes 1 to 6, echovirus serotypes 1 to 9, 11 to 27,
and 29 to 33, and enterovirus serotypes 68 to 71). 5] A total of 785 serum samples
were obtained from a cross-sectional epidemiological survey in the province of
Utrecht, The Netherlands, aimed at the evaluation of the national vaccine program.
Statistical methods
Regression analysis was used to determine the coefficients of correlation between
results obtained by the PoBI test and neutralisation titers. P values of <0.01 were
considered significant.
Results
Optimisation and properties of the PoBI test
We compared different incubation times in order to be able to reduce the duration of
the PoBI test. Pre-incubation of the serum-virus mixture could be reduced to 2 h at
37°C (instead of an overnight incubation at 37°C) without loss of sensitivity or
changes in PoBI titers. Incubation times of the detecting monoclonal antibody and
conjugate were reduced to 1 h at 37°C without influencing the outcome of the assay.
The PoBI configuration (serum-virus pre-incubation) was compared to the direct
binding of the antigen to the IgG in the ELISA plates. The PoBI titers were found to
be 4- to 16-fold higher when the pre-incubation step was performed, and the
correlation with NT was higher (result not shown).
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Specificity of the PoBI test
When the previously described protocol [1] was used, 5.2%, 9.4% and 6.3% of the
negative control samples tested positive in the PoBI test for serotypes 1, 2 and 3,
respectively. The specificity of the assay was increased with the addition of 0.5 M
NaCl in the ELISA dilution buffer to reduce aspecific binding, and this modification
was used throughout the rest of the study. Using this assay format, the specificity was
improved to 99.0%, 95.8% and 100% for serotypes 1, 2 and 3, respectively. Different
blocking agents (BSA, fetal calf serum and milk powder) had no influence on false-
positive results with sera from known seronegative donors. False-positive signals
were strongly reduced or disappeared after (NH4)2SO4 precipitation of the sample,
indicating that the signal was not caused by cross-reacting IgG in the serum sample
(data not shown).
Sensitivity of the PoBI test
The sensitivity of the PoBI test was determined with sera from IPV- and OPV-
vaccinated blood donors and from naturally immune older persons (before and after
IPV vaccination). Overall, the sensitivity was 99.5%, 100% and 96.2% for the
serotype 1, 2 and 3 assays, respectively. The sensitivity of the PoBI test is dependent
on the NT titer and was lowest for sera with low levels (titer, £16) of neutralising
antibodies (95%, 100% and 75% for serotypes 1, 2 and 3 respectively). The sensitivity
increased to 100% at neutralisation titers of 16 and 64 for serotypes 1 and 3
respectively (data not shown).
Cross-reactivity of the PoBI test.
Hyperimmune rabbit sera were used to check for possible cross-reactivity between
antibodies to poliovirus and other enteroviruses in the PoBI test (Table 1). Sera to
other enteroviruses (coxsackievirus B serotype 1 to 6; echovirus serotypes 1 to 9, 11
to 27, and 29 to 33; and enterovirus serotypes 68 to 71) did not react in the PoBI test
for serotypes 1 and 3. In the serotype 2 test, low levels of cross-reactivity were
observed with 13 of the 41 antisera that were tested. In addition, moderate levels of
cross-reactivity were detectable between the polioviruses in the PoBI test and the NT
(Table 1).
Correlation between the PoBI titer and the NT
We found a high correlation between the NT and the PoBI test similar to that
described by Edevag et al. [1] with serum samples from IPV-vaccinated persons
(0.97, 0.95 and 0.94 for serotypes 1, 2 and 3, respectively). The coefficient of
correlation between the NT and the PoBI test for serotypes 1 and 2 was high in OPV-
vaccinated blood donors and naturally immune persons (Table 2). However, the
correlation coefficient was significantly lower for serotype 3 in OPV-vaccinated
blood donors (0.73) and naturally immune persons (0.76) than in the IPV-vaccinated
blood donors (P <0.01) (Table 2). The correlation between PoBI and NT titers was
similar for sera collected at different points in time after the vaccination of naturally
immune persons vaccinated with IPV (Table 2).
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Table 1. Cross-reactivity of sera from rabbits immunised with different enteroviruses
in the Poliovirus-Binding Inhibition assay and neutralisation test.
Rabbit reference NT titer to: PoBI titer to:
serum to: Serotype 1 Serotype 2 Serotype 3  Serotype 1 Serotype 2 Serotype 3
Poliovirus
Serotype 1 20,480 10 <10 4,096 16 4
Serotype 2 10 81,920 <10 64 16,384 4
Serotype 3 <10 <10 40,960 8 8 2,048
Coxsackievirus B




24-27, 29-33 <2 <2 <2 <2 <2 <2
Serotype 7-9,
11-14, 21-23 <2 <2 <2 <2 2 <2
Serotype 20 <2 <2 <2 <2 8 <2
Enterovirus
Serotype 68, 71 <2 <2 <2 <2 4 <2
Serotype 69, 70 <2 <2 <2 <2 <2 <2
Table 2. Correlation of Poliovirus-Binding Inhibition assay and neutralisation test in
groups of persons with vaccine-induced or natural immunity.
Serotype 1 Serotype 2 Serotype 3 n=
Blood donors :
IPV-vaccinated 0.97 0.95 0.94 26
OPV-vaccinated 0.91 0.95 0.73* 42
General population : 0.89* 0.89 0.84 747
Naturally immune : 0.90 0.87 0.76* 47
   Weeks after IPV vaccination :
1 0.80 0.79 0.84 47
4 0.79 0.76 0.84 47
NOTE * significantly different from IPV vaccinated blood donors at the 0.01 level. IPV= inactivated
poliovirus vaccine, OPV= oral poliovirus vaccine.
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Evaluation of immunity in the general (IPV-vaccinated) population
A total of 785, 763 and 771 sera were examined in PoBI and NT for serotypes 1, 2
and 3 respectively. In the general population, the correlation between NT and PoBI
was 0.89, 0.89 and 0.84 for serotypes 1, 2 and 3, which was significantly lower than
the correlation between NT and PoBI using sera from IPV vaccinees for serotype 1
(Table 2). No differences in the correlation between PoBI and NT were found
between the different age groups (data not shown). From the regression line, the PoBI
titer that corresponds with a titer in the NT of 8 was calculated to be 4 [Figure 1].
Therefore, sera with a PoBI titer < 4 were considered negative. The sensitivity of the
PoBI test was high for all three serotypes: 98.6%, 97.4% and 92.1% for serotypes 1, 2
and 3 respectively. The positive predictive value of the PoBI test in the general
population was 0.98, 0.97 and 0.97 for serotypes 1, 2 and 3 respectively. Specificity in
this group was 80.3% for serotype 1, 82.0% for serotype 2 and 79.8% for serotype 3.
The negative predictive value was 0.83 and 0.82 for type 1 and 2 respectively, and
only 0.61 for type 3.
Both assays provided a normal distribution of titers in addition to a group of
seronegatives (PoBI and NT titers of <4 and <8 respectively) for all three serotypes
[Figure 2]. PoBI titers were generally two-fold lower than the standard NT titers.
The total number of seronegatives in the general population was estimated to be 7.5%,
12.4% and 17.4% with the PoBI and 7.8%, 12.5% and 13.3% with the NT test. These
percentages were not significantly different (p-level <0.01). The PoBI was able to
provide a good estimate of the total number of seronegatives for all three serotypes
within the different age groups in the general population [Figure 3], and showed
patterns of seroprevalence in the different age groups similar to the NT for all three
serotypes.
Discussion
Previously described ELISAs used to measure protective antibodies to poliovirus
could not compete with the very sensitive NT [6,7,10,17]. With a direct ELISA
format for serotype 1, Simhon et al. [17] reached positive predictive values between
0.82 and 0.91, but found high numbers of false-negative results and low negative
predictive values (between 0.29 and 0.55). Hagenaars et al. [7] described an inhibition
ELISA in which serum antibodies and labelled bovine anti-poliovirus serotype 1
competed for binding places on the bound antigen. The assay correlated well with NT
but the standard NT assay was more sensitive then the inhibition ELISA.
The present format of the PoBI test, in which inhibition of the signal depends on both
reduction of virus-antigen binding to the capture antibody and reduction of binding of
the indicator monoclonal antibody, was found to be a suitable replacement for the NT
in large scale population studies. Although PoBI titers were generally (two-fold)
lower than NT titers, neutralisation positive samples could easily be identified.
Sensitivity and positive predictive values were high in both IPV- and OPV-vaccinated
persons as well as in naturally exposed people. The specificity of the PoBI test was
determined with selected sera from non-vaccinated subjects and was high (95-100%).
In the general population, persons with low NT titers (2 and 4) are considered to be at
risk for poliovirus-induced disease. Therefore, for the purpose of this evaluation, sera




Figure 1. Correlation between the NT and PoBI titers (expressed as 2log values) for the three
poliovirus serotypes in a cross-section of different age groups in the general population.

















































Figure 2. Frequency distribution of NT and PoBI titers (expressed as 2log values) in a cross-
section of different age groups in the general population. Results are presented as
percentage of persons positive per titer. The highest serum dilution tested in the PoBI was
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Figure 3. Seroprevalence of poliovirus antibodies in a cross-section of different age groups in
the general population as determined by PoBI and NT assay. Results are expressed as
percentage seropositives per age group. NT titers were considered positive if the titer was ³
8. PoBI titers were considered positive if the titer was ³ 4.
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were considered seronegative. The detection of these low NT titers in the PoBI is
responsible for the lower specificity of the PoBI calculated from the comparative
serology in the population (79.8-82.0%) as well as for the low negative predictive
value for the serotype 3 assay.
The question remains whether NT titers of 2 and 4 are truly negative or whether they
should be considered low but specific antibody levels. It is most likely that this group
consists of both true negatives and low positive samples. Therefore, PoBI-negative
sera should be re-tested by NT. The PoBI results with rabbit hyperimmune sera
showed that cross-reactivity with other enteroviruses did not occur for serotype 1 and
3, and only at low levels for type 2. Since titers to enterovirus antigens as high as the
levels found in the hyperimmune rabbit serum samples are not likely to be detected in
the general population or in patients, this low level cross-reactivity is not a problem
for serosurveys in which the PoBI is used.
The purpose of this seroprevalence study was to estimate the total number of
seronegatives (as determined by NT and by PoBI) within the Dutch population. A
high percentage of seronegatives in the population indicates a potential risk for
poliomyelitis outbreaks and requires active re-vaccination of the (age) groups at risk.
The PoBI test proved to be an excellent indicator of seroprevalence in all age groups
from an IPV-vaccinated population. Both assays yielded similar estimates of the total
number of seronegatives within the general population for all three serotypes.
We conclude that the PoBI is a suitable test for seroprevalence studies of poliovirus. It
is a less labour intensive assay than the NT, it is easier to perform, it can be further
automated and it is not dependent on a visual screening of the cytopathic effect as is
the case in the standard NT. This assay could be used for population screening when
combined with confirmatory testing of PoBI negatives by the NT. Given the current
prevalence of poliovirus antibodies, this approach could reduce the total number of
serum samples examined in the NT by 87.5%.
We reached a high correlation between PoBI and NT similar to that described by
Edevag et al. [1] for IPV-vaccinated subjects. However, OPV vaccine recipients and
naturally immune persons provided correlations between PoBI and NT titers against
serotype 3 that were significantly lower. These correlations tended to be lower for the
other serotypes as well. This may be explained in part by the use of IPV vaccine (and
not OPV) as antigen in the PoBI. The greater difference observed in the serotype 3
PoBI test may be explained by a narrower immune response against serotype 3
poliovirus as compared with the other serotypes. In animals, site 1 of serotype 3 is
extremely immunodominant [3,9]. Therefore, the polyclonal coat for the serotype 3
PoBI may consist mainly of (neutralising) antibodies to site 1, and as a result may be
very sensitive to changes in immune response directed to site 1.
In this context, it is intriguing that differences in immune responses have been
observed between infection by wild-type 3 poliovirus or OPV at the one end and IPV-
induced immunity at the other. During infection with live viruses (wild-type or OPV),
site 1 of serotype 3 is cleaved by trypsine during the passage through the gut lumen,
thereby exposing other immunogenic sites on the viral capsid [14,15]. This trypsine
effect will not occur in IPV-recipients because the vaccine is given by intramuscular
injection. The trypsin-dependent immunogenic sites will therefore be less well
exposed to the immune system. In contrast to serotype 3, the PoBI assays for
serotypes 1 and 2 are probably reactive with antibodies to more than one antigenic site
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so that differences between OPV- and IPV-vaccinees are not detected. Future work
will focus on the site-specificity of the human antibody response to poliovirus.
In conclusion, the newly developed PoBI test can replace NT in large scale population
studies for determining protective levels of antibodies to polioviruses. PoBI negative
sera should be re-tested by NT for confirmation of seronegativity. One of the major
advantages of the PoBI over the NT is that inactivated virus is used. In view of the
ongoing eradication of poliovirus, the use of live wild-type poliovirus in diagnostic
assays should be discouraged and eventually cease altogether in the near future.
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Differences in the antibody responses to
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Three important antigenic sites involved in virus neutralisation have been identified
on polioviruses in mouse experiments. These sites are located at the surface of the
virion and have been designated antigenic sites 1, 2 and 3. The antibody response to
antigenic site 1 of serotype 3 poliovirus is considered to be immunodominant in mice,
but little is known about the immunogenicity of these sites in humans. It has been
reported that trypsin, present in the intestinal fluids, can cleave serotype 3
polioviruses at precisely this immunologically important antigenic site, thereby
altering its antigenic properties. In theory, therefore, the site-specific antibody
response induced by intramuscularly-applied inactivated poliovaccine will differ from
that induced by orally-administered live poliovirus that has been exposed to trypsin in
the gut lumen. In the present study, we developed inhibition ELISA assays specific
for (mouse) antigenic sites 1 and 3 in order to measure antibody responses to these
sites in fully-vaccinated IPV (n=63) and OPV-recipients (n=63), and in naturally
infected persons (n=25). We found that both sites are strongly immunogenic in
humans. Similar levels of site-specific antibodies were found for sites 1 and 3 in
naturally infected persons. Similar levels of antibodies to site 1 were detected in IPV
and OPV vaccinees. However, significantly more OPV recipients (88.7%) had
detectable antibodies to antigenic site 3 (p<0.01) when compared to IPV-vaccinated
persons (63.1%). Both previously IPV- and OPV-vaccinated persons responded with a
significant increase in antibodies to sites 1 and 3 after an IPV booster vaccination
(p<0.01). We conclude that the immune response following natural infection with
serotype 3 poliovirus in humans consists of both site 1- and site 3-specific antibodies,
and that these responses can be induced by OPV or by recent IPV vaccination.
Introduction
The poliovirus capsid consists of 20 copies of each of the four structural virion
proteins (VP1, VP2, VP3 and VP4) [9]. The epitopes responsible for inducing
poliovirus-neutralising antibodies are located on surface-exposed loops in the three
structural proteins: VP1, VP2 and VP3 [3]. VP4 is completely located on the inside of
the viral capsid and plays no known role in the induction of poliovirus-neutralizing
antibodies. VP1 is the most exposed surface protein and plays a major role in the
induction of neutralizing antibodies for all three the poliovirus serotypes [27].
Three important antigenic sites (epitopes) involved in virus neutralisation have been
identified on polioviruses and have been designated as site 1, 2 and 3 [9,15]. These
sites have been identified through the isolation and characterisation of Sabin mutant
strains resistant to neutralisation by poliovirus-specific antibodies and by epitope
mapping using neutralizing monoclonal antibodies [15].
Antigenic site 1, composed of amino acids 89 to 100 of VP1, is a major immunogenic
site for serotype 2 and 3 polioviruses as determined by neutralizing monoclonal
antibodies induced in mice [15]. This site is usually immunorecessive in serotype 1
poliovirus [22]. Antigenic site 2 is a complex site including residues 220 to 222 of
VP1 (site 2a) as well as residues 169 and 170 on VP2 (site 2b) [15]. Sites 2a and 2b
have both been detected in serotype 1 poliovirus, while only site 2b has been detected
in serotype 3 poliovirus. Site 3 is also a complex site and includes the residues 286 to
290 from VP1 (site 3a) as well as the residues 58 and 59 and others from VP3 (site
3b). Both sites 3a and 3b have been detected in serotype 3 poliovirus, while
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neutralising antibodies to site 3b have been detected in serotype 1 poliovirus only,
suggesting that site 3a is not immunogenic in serotype 1 poliovirus [22].
The location of the amino residues within the three dimensional structure of the virion
indicates that the majority of these amino acids residues are highly exposed and
located within prominent structural features of the viral surface [21]. A deep canyon
or pit on the surface of poliovirus has been identified as the receptor binding site [5].
The neutralising epitopes themselves are not involved in receptor binding, but binding
of antibodies to these spots probably causes steric hindrance with the actual receptor
binding site within the canyon [5]. Whether all these sites are also antigenic for
humans is not clear.
It has been reported that trypsin treatment can cleave both serotype 1 and serotype 3
polioviruses at antigenic site 1 at residue 98 (arginine) [4,11,23,25]. While the
poliovirus retains its infectivity in both cases, its antigenic properties are drastically
altered, and the trypsin-cleaved viruses are not neutralised or immunoprecipitated by
monoclonal antibodies to site 1 of non-treated virions [11]. This trypsin effect will not
occur in IPV recipients who have received the vaccine through intramuscular
injection. If antigenic site 1 of poliovirus serotype 3 is also immunodominant in
humans, vaccination with IPV could theoretically induce predominantly neutralizing
antibodies to site 1, leaving a possible gap in the immune response to trypsin cleaved
serotype 3 poliovirus [9,15].
This study compared the site-specific humoral immune responses of naturally infected
and IPV- or OPV-vaccinated persons for poliovirus serotype 3. The effect of an IPV
booster vaccination on the site-specific antibody titers was also examined.
Materials and methods
Serum samples
Negative control serum samples were used to test the specificity of the antigenic site
1- and 3-specific assays. These samples were obtained from non-vaccinated children
(n=20) from a religious group in The Netherlands that refuses vaccination. The sera
had been pre-screened by neutralisation test for absence of neutralising antibodies to
poliovirus (titer, <2) [6]. The seroprevalence of antigenic site 1- and 3-specific
antibodies after vaccination was determined for sera from IPV-vaccinated healthy
blood donors (n=63) and from age-matched OPV-vaccinated blood donors from
Belgium (n=63) who had received a complete series of vaccination as children [6].
The IPV-vaccinated (n=11) and OPV-vaccinated subjects (n=10) were given an IPV
booster vaccination to determine the influence of IPV vaccination on the induction of
antigenic site 1- and 3-specific responses for the different vaccine backgrounds. Blood
samples were collected before booster vaccination and at 3, 7 and 28 days post-
vaccination. Full details of this study have been described elsewhere [8]. Serum
samples from poliomyelitis patients (n=25) from the 1992/1993 serotype 3 epidemic
in The Netherlands were tested to determine antigenic site 1- and 3-specific responses




A panel of serotype 3-specific monoclonals with specificity for antigenic site 1, 2 or 3
was used to test the newly developed assays for specificity. The monoclonals 204 (site
1), 877 (site 2) and 889 (site 3) were kindly donated by Dr. Ferguson (NIBSC, UK)
[14,15,22]. Monoclonals 2-13D9 (site 1), 2-15E4 (site 1) and 4E5E9 (site 2/3) were
produced at the RIVM (Bilthoven, The Netherlands) [12,20].
Virus preparation
Sabin mutant virus strains 335 (site 1) and 4021 (site 3) (kindly provided by Dr
Ferguson) were grown on Hep-2C cells in Eagle MEM supplemented with 10% FCS,
until full cytopathic effect developed [14]. The culture supernatant was collected and
centrifuged for 30 min at 3000 rpm to remove cell debris. The supernatant was
extracted with 10% v/v arklone at 4°C for 45 min during constant shaking followed
by centrifugation (30 min, 3000 rpm). The supernatant was concentrated by direct
ultrafiltration using membranes with a molecular weight cut-off of 10kD (type PM10;
Amicon) [24]. The optimal working dilution of the concentrated virus in the site-
specific assay was determined by checkerboard titration.
Antigenic site 1-specific Poliovirus-Binding Inhibition assay (PoBI)
The site-specific PoBI assays were a modification of the previously described PoBI
assay [6], except that monoclonal antibodies to specific sites were used as capture
antibodies in the ELISA. The inhibition of the ELISA signal depends on both
reduction of virus-antigen binding to the capture antibody due to the presence of
competing (blocking) antibodies as well as reduction of binding to the indicator
monoclonal antibody by the same mechanism. Briefly, two-fold dilutions of serum
samples were made directly into the wells of microtiter cell culture plates (Greiner,
Alphen aan de Rijn, The Netherlands) and poliovirus antigen was added to each well.
The antigenic site 3 Sabin mutant strain 4021 (kindly provided by Dr. Ferguson) was
used as antigen to prevent cross reactivity with this antigenic site [14]. Serum-virus
mixtures were incubated for 2 hours at 37°C. After washing of the plates, the pre-
incubated serum-virus mixture was transferred to ELISA plates, that had been coated
overnight with the antigenic site 1-specific monoclonal 2-13D9 (IgG isotype) in a
dilution of 1/8000 [12]. After the incubation, the homologous monoclonal antibody
(2-13D9), labelled with horseradish peroxidase, was used to detect bound poliovirus
[18]. TMB was used as a substrate, and colour development was stopped after 15
minutes by the addition of 2M H2SO4. The plates were read at 450nm. Serum samples
were considered positive if a reduction in extinction of ³50% was reached. The
reciprocal of the first serum dilution that was positive in the inhibition test was taken
as the titer of the test sample. For specificity testing, serum was replaced by serial
dilution of monoclonals to site 1, 2 and 3. Optimal dilutions of reagents were
determined by checkerboard titration.
Antigenic site 3-specific PoBI
The antigenic site 3-specific assay was conducted in a manner similar to the site 1
assay described above, using site 3-specific IgM monoclonal 889 as a capture
antibody in the PoBI. These IgM molecules were first degraded into F(ab’)2
Differences in antibody responses to antigenic sites 1 and 3
50
fragments by pepsin according to the manufacturer’s instructions [Pierce, Rockford,
USA], since IgM antibodies cannot be coated efficiently [1]. The Sabin mutant strain
335 (kindly provided by Dr. Ferguson) was the antigen used to reduce cross-reactivity
within the antigenic site 1 [14]. Biotin-labelled antigenic site-3 specific monoclonal
889 was used to detect bound antigen. Avidin conjugated with alkaline phosphatase
(Sigma, Zwijndrecht, The Netherlands) was added and incubated for 1 hour at 37°C.
The plates were washed, and 100 µl of p-nitrophenylphosphate at a concentration of
1mg/ml in 0.1 M glycine buffer was added to each well. The plates were read at 405
nm after incubation at room temperature for 30 minutes. Results were analysed as
described for the site 1-specific assay.
Poliovirus-Binding Inhibition assay (PoBI)
A Poliovirus-Binding Inhibition assay (PoBI) was used to determine the total number
of poliovirus-specific antibodies as an indicator of neutralizing antibodies, and was
performed as described [6]. Serum samples were considered positive if a reduction in
extinction of ³50% was reached. The reciprocal of the first serum dilution that was
positive in the inhibition test was taken as the titer of the test sample.
Statistical methods
An unpaired Student’s t-test was used to evaluate the differences between the titers of
site-specific antibodies to poliovirus between two groups. P values of <0.01 were
considered significant.
Results
Specificity of the antigenic site 1- and site 3-specific PoBI serotype 3 assays
None of the negative control serum samples tested (n=20) showed any inhibition of
the antigenic site 1 and site 3 PoBI signal (data not shown). A panel of monoclonals
was used to test the site specificity in the site 1 and site 3 PoBI assay. The antigenic
site 1-specific monoclonals 2-13D9 (titer, >12800; homologous), 2-15E4 (titer,
12800) and 204 (titer, >12800) were able to inhibit the antigenic site 1 PoBI signals,
whereas none of the monoclonals (4E5E9, 877, 889) to antigenic sites 2 and 3 of
serotype 3 poliovirus did so (titer, <100). In the site 3-specific assay, the homologous
monoclonal was able to inhibit the PoBI signal at a high level (titer 6400), and only
low level cross-reactivity was detected with site 1-specific monoclonals 204 (titer,
200), 2-15E4 (titer, 400) and 2-13D9 (titer, 400).
PoBI and antigenic site 1- and site 3-specific immune responses in poliomyelitis
patients
Twenty-five patients from the 1992/93 serotype 3 outbreak in The Netherlands were
tested using the site-specific assays [19]. A median antibody titer of 2log 6 to both
antigenic site 1 and 3 was detected in all patients [Figure 1].
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Figure 1. PoBI titers and, antigenic site 1 and 3-specific antibody titers in patients with
paralytic poliomyelitis (n=25), IPV- (n=63) and OPV- (n=63) vaccinated blood donors. Results
are expressed as 2log titers. Horizontal lines indicate the median value. (*= p<0.01, NS =not
significant).
PoBI and antigenic site 1- and site 3-specific immune responses in IPV- and
OPV- vaccinated subjects
PoBI titers in IPV vaccinated persons were, on average, 8 fold lower than in naturally
immune persons (p<0.01) and 4 fold higher than in OPV recipients (p<0.01). There
was no significant difference in the median titers to antigenic site 1 and site 3 of
serotype 3 poliovirus between the IPV- and OPV-vaccinated groups, although the
median titer for site 3 was 1 log step higher in OPV-vaccinated persons [Figure 1].
However, a significantly higher proportion of OPV-vaccinated persons (88.7%) had
site 3-specific antibodies compared to IPV-vaccinated persons (63.1%) (p<0.01)
[Table 1]. No differences were observed in the proportions of positive IPV and OPV
recipients in the PoBI assay (66.2% versus 75.8%) and the antigenic site 1-specific
assay (72.3% versus 64.5%) [Table 1].
Table 1. Proportions of IPV and OPV vaccinated persons with detectable poliovirus-
specific antibodies in the PoBI, site 1- and site 3-specific assays.
IPV OPV p-value
PoBI 66.2% 75.8% p=0.32
Site 1 72.3% 64.5% p=0.45
Site 3 63.1% 88.7% p<0.01
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Figure 2. Antigenic site 1- and site 3-specific responses after IPV booster vaccination of
previously IPV (n=11) and OPV (n=10) vaccinated persons. Results are expressed as 2log
titers. Horizontal lines indicate the median value. (*= p<0.01, NS =not significant).
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PoBI and antigenic site 1- and site 3-specific immune responses after IPV booster
vaccination in IPV and OPV recipients
A significant booster of the antigenic site 1- and site 3-specific antibodies and PoBI
titers was detected in both IPV and OPV recipients at 7 and 28 days compared to day
0 and 3 after booster vaccination with IPV (p<0.01). However, the detected increase
in titers was smaller in the IPV recipients compared to OPV recipients (p<0.01)
[Figure 2].
Discussion
The data presented in this paper clearly indicate that both antigenic site 1 and site 3
are immunogenic in humans, as antibodies specific for these sites were detected after
natural infection and in IPV- and OPV-vaccinated persons. These results differ from
those in mice experiments [9,15], because site 1 does not appear to be as
immunodominant in humans. Similar levels of both site 1- and site 3-specific
antibodies were readily detected in those who had been naturally exposed as well as in
IPV- and OPV-vaccinated persons.
We used site-specific inhibition ELISA assays to measure antibody levels to antigenic
site 1 and site 3. The inhibition levels reached in the site 1- and site 3-specific assays
with the homologous antibodies were very high (site 1: >12800; site 3: 6400). The site
1 assay proved to be completely site-specific. Some cross-reactivity was detected in
the site 3-specific assay with monoclonals to the antigenic site 1, but titers were 64-
fold lower. Titers to poliovirus antigen as high as the levels found in the homologous
reactions with the monoclonals are not likely to be detected in the general population
or in patients. For this reason, low level cross-reactivity is not considered to be a
problem for the estimation of the level of antibodies to site 3 when human sera are
tested.
No significant difference was observed in the immune response between OPV and
IPV recipients with respect to antigenic site 1 of serotype 3 poliovirus. However,
significantly more OPV-vaccinated persons had detectable antibodies to antigenic site
3 (88.7%) compared to IPV recipients (63.1%). It is conceivable that the lower
number of site 3 seropositives in the IPV-vaccinated group (compared to the OPV
vaccinated group) can be explained by trypsin cleavage of site 1 after passage of the
OPV strains through the gut lumen [23,25]. Field trials using regular IPV or trypsin-
treated serotype 3 Saukett strains (IPV) demonstrated that both vaccines induced an
increase of neutralising antibody titers to intact and trypsin-treated virus, but the
response was not studied at the level of individual antigenic sites [23]. Alternatively,
the difference between the number of positives in the OPV-vaccinated group and the
number in the IPV-vaccinated group may be explained by a longer lasting induction
of site 3-specific antibodies. Site 3-specific antibodies were induced in previously
IPV-vaccinated individuals after IPV booster vaccination. Tests using sera from
people who had been vaccinated less recently, however, provided a lower number of
positive results for site 3-specific antibodies.
It is conceivable that the site 3-specific antibodies in some of the IPV and OPV
recipients are attributable to previous natural exposure to live poliovirus (wild-type or
OPV strains). The high seroprevalence of IgA in the circulation of IPV-vaccinated
persons probably indicates mucosal contact with poliovirus [7,8]. Poliovirus is no
longer endemic in The Netherlands, but in 1992 a large outbreak of serotype 3
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poliovirus occurred [19]. While widespread circulation during this epidemic was not
demonstrated [2,16,26], part of the vaccinated population may have come into contact
with the circulating wild-type strain or OPV strains that were used to control the
epidemic. Similarly, the trypsin exposure of OPV in the gut may result in reduced
immunogenicity of antigenic site 1, favouring the development of site 3-specific
antibodies. However, 49.0% of the IPV recipients in this study had site 3-specific
antibodies in the absence of an IgA response (data not shown). These results might
indicate that site 3 responses are longer lasting than the serotype 3-specific IgA in the
circulation after mucosal contact. Alternatively, the site 3-specific antibodies may
have been induced by IPV only.
Persons with no neutralizing antibodies to antigenic site 3 might not have an effective
response to polioviruses with an altered antigenic site 1. The importance of site 3 for
protection against poliomyelitis is illustrated by the Finland epidemic of 1983 [10], in
which the serotype 3 endemic poliovirus strain was altered in antigenic site 1 [13].
This outbreak was also influenced by low antibody titers to serotype 3 poliovirus in
the general vaccinated population [13]. In addition, the significantly lower antibody
titers to the altered virus reflect the possible dangers of a reintroduction of antigenic
site 1 variants or their actual generation in persons with no site 3-specific antibodies.
Recently, we described a serotype 1 Sabin virus with a 6 aminoacid deletion in
antigenic site 1 [17]. Neutralisation of this mutant strain by an antigenic site 1
monoclonal was altered. While this strain was still effectively neutralised by sera
from IPV and OPV vaccinees, our present findings suggest that neutralising activity
should be investigated in persons with and without site 3-specific antibodies in order
to estimate the risk of infection with mutant viruses.
In conclusion, we observed that the immune response following natural infection with
serotype 3 poliovirus in humans consists of both site 1- and site 3-specific antibodies.
No significant difference was observed between IPV and OPV recipients’ immune
responses to antigenic site 1. Responses to antigenic site 3 of serotype 3 poliovirus
was detected more frequently in persons who had been vaccinated by OPV in their
childhood than in those who had received IPV. However, site 3-specific antibodies
were increased after IPV-booster vaccination in both groups. These results indicate
that IPV recipients are likely to be sufficiently protected against trypsin treated
serotype 3 poliovirus.
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The inactivated poliovirus vaccine (IPV) is used for protection against poliomyelitis
in The Netherlands. It is not clear if parenteral IPV vaccination can lead to priming of
the mucosal immune system. We developed and evaluated ELISA assays for the
detection of poliovirus-serotype-specific IgA and secretory IgA antibodies. Using
these assays, we examined the kinetics of the IgA response in sequential serum
samples from 15 poliomyelitis patients after natural infection with serotype 3
poliovirus. IgA remained present in 36% of the patients for up to five months post
infection. Furthermore, the presence of IgA antibodies was examined in an IPV-
vaccinated population using sera from young children (4-12 years of age, n=177),
older children (13-15 years of age, n=123), healthy blood donors (n=66) and naturally
immune elderly persons (n=54). Seroprevalence of IgA was low in young vaccinated
children for all three serotypes (5%-7%), and in older vaccinated children for types 2
and 3 (2%-3%). Seroprevalence for type 1 was significantly higher (18%) in older
children than in younger children. This higher seroprevalence is most likely explained
by the persistence of IgA following infection with the serotype 1 wild type poliovirus
strain during the 1978 epidemic. The seroprevalence of type 1- and 2-specific IgA
was significantly higher in healthy adults than in young children. These results
suggest that at least part of the IgA found in the older population is induced by
infections unrelated to the IPV vaccination schedule. Finally, we found that parenteral
IPV vaccination was able to boost (secretory) IgA responses in 74%-87% of a
naturally exposed elderly population (n=54). While the presence of (s)IgA in IPV-
vaccinated persons has been previously documented, our findings suggest that
mucosal priming with live virus is necessary to obtain an IgA response after IPV
booster vaccination.
Introduction
Systemic antibody responses to poliovirus infection and vaccination (with live or
inactivated virus) have been extensively studied. The presence of circulating
neutralizing antibodies is sufficient for protection against paralytic disease [13]. In
contrast, less is known about the induction of mucosal immunity, which is important
for the limitation of virus circulation in the community as well as for protection from
infection [7,13].
An important component of mucosal immunity is secretory IgA (sIgA). The presence
of sIgA on mucosal surfaces reduces viral excretion after oral poliovirus vaccine
(OPV) challenge [12]. In theory, intramuscular vaccination by inactivated poliovirus
(IPV) is expected to induce little or no sIgA. However, several studies have measured
some degree of local immunity in IPV vaccinees, albeit less effective immunity than
in people vaccinated orally with OPV or infected with wild virus [3,4,7,8,14].
An inherent difficulty in the comparison of results from different studies lies in the
fact that vaccination schedules and dosages have not been standardised between
countries. It therefore remains unclear whether the superiority of OPV vaccination
over enhanced potency IPV (eIPV) with respect to mucosal immunity applies to the
situation in The Netherlands, where a total of six IPV vaccinations are given at 3, 4, 5
and 12 months, and subsequently at 4 and 9 years of age. In addition, most studies of
mucosal immunity have been conducted with recently vaccinated individuals. This
may not reflect the situation as it applies to older age groups.
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The issue at hand is whether IPV vaccination confers sufficient mucosal immunity to
prohibit virus circulation following introduction in the community. This is particularly
important in The Netherlands, where pockets of religious communities with low
vaccination coverage exist. Epidemics of poliomyelitis occurred in these groups in
1978 and 1992 [5,16,17].
The purpose of this work was to develop poliovirus-specific IgA assays and to study
the kinetics of IgA responses after infection and in an IPV vaccinated population.
Materials and Methods
Clinical samples
The specificity of the poliovirus-specific IgA-ELISAs was tested using serum samples
from persons negative for neutralising antibodies to poliovirus (n=114). These
samples were obtained from non-vaccinated children from a segment of the
population that refuses vaccination for religious reasons. Samples that had titers of
neutralising antibodies of < 1:2 for all three serotypes of poliovirus and that were
negative for antibodies to other components of the vaccine cocktail (diphtheria and
tetanus toxoid) used in the routine immunisation of children in The Netherlands were
considered as true negatives. The sensitivity of the assays was determined using a
panel of sera collected from patients with a proven poliovirus infection within 2.5
months after the onset of paralysis. Patients were from the 1992-1993 serotype 3
outbreak in The Netherlands (n=54) and from the outbreak in Pakistan during 1991-
1995 involving all three serotypes (n=98). Infection was confirmed in all patients by
the isolation of wild-type poliovirus from stool samples and by the detection of
poliovirus-specific IgM in serum by ELISA [11]. Isolated wild-type polioviruses were
discriminated from vaccine-derived viruses by an ELISA using type-specific cross-
absorbed antisera as described previously [20].
Sequential serum samples from 15 patients (age range 1-36 years) from the 1992-
1993 serotype 3 epidemic in The Netherlands were tested for the presence of IgM and
IgA antibodies in order to determine the kinetics of the IgA response after natural
infection. Poliovirus-specific IgM levels in serum samples were determined to
confirm primary infection. Sera from the following groups were investigated to
determine the seroprevalence of poliovirus-specific IgA in an IPV-vaccinated
population:
1] Sera from schoolchildren between 4 and 12 years of age, collected shortly after
IPV vaccination (n=177), or between 13 and 15 years of age (n=123). These serum
samples had been collected during the 1992-1993 outbreak in The Netherlands in
order to check the seroprevalence of neutralising antibodies to poliovirus and to test
for evidence of poliovirus infection within this group. All children had been
vaccinated with IPV, had protective levels of neutralising antibodies to all three
serotypes, and were positive for antibodies to diphtheria and tetanus toxoid (also
included in the vaccine). The younger children (4-12 years) had received four to six
doses of IPV and the older schoolchildren (13-15 years) had completed the IPV
vaccination schedule several years previously.
2] Sera from fully IPV-vaccinated healthy blood donors were tested to determine the
long term persistence of IgA after vaccination (n=66). This latter group was compared
Chapter 4
61
with age-matched blood donors from Belgium (n=66) where OPV is used in the
national vaccination program (OPV at 3, 4, 5 12 months, and at 6 and 12 years of
age). The age range of both groups of blood donors was between 18 and 65 years
(average 39 years).
3] Sera from a group of non-vaccinated older persons from The Netherlands (52-85
years, n=54) who had been given a single dose of IPV were examined for the presence
of neutralising antibodies and poliovirus-specific IgA. This group was expected to be
naturally exposed at a young age when poliovirus was endemic in The Netherlands.
Sera were collected at the time of IPV vaccination and at 1 and 4 weeks thereafter.
IgA-ELISA
Wells of microtiter plates (Nunc, Maxisorb) were coated overnight at + 4°C with
serotype-specific monoclonal antibody to poliovirus at a concentration of 0.6 to 1.2
µg/ml in 0.04 M carbonate-bicarbonate buffer (pH 9.6). The monoclonal antibodies
used were 5-18D8 for poliovirus type 1, 1-10C9E6 for type 2, and 2-13D9 for type 3
[15]. Negative control wells were coated with a monoclonal antibody to influenza A
virus (6-21/19-6, A/Singapore/6/86 (H1N1) strain-specific). After blocking for 1 hour
at 37°C with 5 % Blotto (Pierce, Oud Beijerland, The Netherlands) in PBS containing
0.05 % Tween 20, 40 to 70 D-antigen units (the form found in the infectious virus) of
formaldehyde-inactivated poliovirus were added to each well. We used the inactivated
Mahoney strain for the type 1, MEF for the type 2, and Saukett for the type 3 assay,
all from the vaccine production facility of the National Institute of Public Health and
the Environment (RIVM). Poliovirus strains were originally derived from the
American Type Culture Collection (ATCC). The plates were incubated for two hours
at 37°C. Phosphate-buffered saline containing 0.5% Tween 20 and 2% Blotto was
used as a dilution buffer. Volumes of 100µl were used, and plates were washed four
times in PBS with 0.05% Tween 20 between each incubation step. In parallel wells,
dilution buffer without virus was added to control for non-specific binding of sera.
Prior to testing, sera were depleted of IgG with Quik-Sep (Isolab, Mechelen,
Belgium) according to the manufacturer’s instructions to prevent possible inter-
isotype competition. Serum dilutions of 1/50 were added to the plates and incubated
overnight at + 4°C. After washing, an optimal dilution (1/8000) of goat-anti-human
IgA labelled with alkaline phosphatase (alfa-chain specific, Sigma, Zwijndrecht, The
Netherlands) was added and incubated for 1.5 hours at 37°C. The plates were washed
and 100 µl per well of P-nitrophenylphosphate was added at a concentration of 1
mg/ml in 0.1 M glycine buffer (pH 10.4). After incubation at room temperature for 30
minutes the plates were read at 405 nm by use of an Organon Teknika microwell
system 510 spectrophotometer. A serum sample was considered positive if the optical
density (OD) was above the cut-off level, defined as the average OD + 3 standard
deviations of results obtained with negative control sera from non-vaccinated persons
(n=114). At least one IgA positive (derived from an OPV-vaccinated subject) and one
IgA negative control serum was included on each plate. Optimal dilutions of
monoclonal antibodies, viral antigen, sera, and detector antibodies were established
by checkerboard titrations. The reagent dilutions chosen for this test provided the
highest OD differences between signal and background levels. Specificity of positive
signals was confirmed by blocking experiments in which serum samples were pre-
incubated with homologous poliovirus (± 120 D-antigen units) for 2 hours at 37°C,
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and centrifuged for 3 minutes at 10.000 rpm to remove immune complexes prior to
testing in ELISA. A reduction of the signal of >50% was considered confirmative.
Secretory IgA capture ELISA
A capture ELISA was used to investigate the sera of the older population to determine
if IgA detected after IPV vaccination was also present in its secretory form. The assay
was a modification of the IgM ELISA that has been described previously [11].
Briefly, microtiter plates were coated with monoclonal antibody against secretory
component (Sigma, Zwijndrecht, The Netherlands) overnight at 4°C in carbonate
buffer. Plates were blocked with 5% normal goat serum, serum dilutions (1:50) were
added, and the plates were incubated for 1.5 hours at 37°C. Formaldehyde-inactivated
poliovirus type 1, 2 or 3 was added as described, and bound antigen was detected with
horseradish-peroxidase-labelled serotype-specific monoclonal antibody (1 hour,
37°C). Tetramethylbenzidine (TMB) was used as a substrate (0.1 mg/ml) in 0.11 M
sodiumacetate buffer, and the reaction was stopped after 30 minutes with 2M H2SO4.
Serum samples were considered positive if responses were above the cut-off level,
defined as the average optical density (OD) + 3 standard deviations of results obtained
with negative control sera from non-vaccinated persons (n=114). At least one sIgA
and one sIgA negative control serum was included on each plate.
Poliovirus type-specific IgM-antibody capture ELISA
The IgM-ELISA was performed as described previously [11]. In brief, wells of
microtiterplates were coated overnight at 4°C with 100µl of µ-chain-specific
monoclonal antibody to human IgM (Sanbio BV, Uden, The Netherlands) at a dilution
of 1:100 in PBS, supplemented with 0.5% Tween 20, and 5% fetal calf serum. Serum
dilutions (1:50) were added and were incubated overnight at 4°C. Inactivated
poliovirus suspension containing between 40 and 70 D-antigen units was added and
incubated for 2 hours at 37°C. Bound antigen was detected by horseradish-
peroxidase-labelled serotype-specific monoclonal antibodies (1 hour, 37°C). TMB
was used as substrate, and colour development was stopped after 12 minutes by the
addition of 2M H2SO4. A positive and a negative control serum and a
positive/negative cut-off control serum were examined in each assay. The
positive/negative cut-off serum was prepared on the basis of comparison with the
distribution of the OD450 values obtained with sera from both patients and healthy
controls. A ratio of >1 between the sample OD450 and the cut-off serum OD450 was
considered to indicate the presence of poliovirus-specific IgM in the sample.
Neutralisation assay
Poliovirus neutralising antibody titers (NT) of sera were determined in the standard
microneutralisation test as recommended by the WHO [21], using Mahoney (serotype
1), MEF (serotype 2) and Saukett (serotype 3) virus strains as challenge viruses.
Statistical Methods
A Chi-square analysis was performed to determine the significance of the difference




Specificity and sensitivity of the poliovirus-specific IgA ELISAs
The specificity of the poliovirus-specific IgA-ELISAs was 100%, 99%, and 99% for
poliovirus serotypes 1, 2 and 3 respectively. Poliovirus-specific IgA was detected in
89%, 81% and 90% of the serotype 1, 2 and 3 samples from infected patients. Positive
signals in the ELISA could only be blocked by pre-incubation with the homologous
poliovirus and not with heterologous virus (results not shown).
Kinetics of IgA production in patients infected with wild type poliovirus
All type 3-infected poliomyelitis patients (n=15) had poliovirus serotype 3-specific
IgA and IgM antibodies in at least one of the serum samples. Four patients had IgA
antibodies to all three serotypes, and one patient had IgA against type 1 and 3.
Poliovirus serotype 3-specific IgA reached a peak at three to four weeks after onset of
paralysis [Figure 1] and decreased to low levels within three months. Thirty-six
percent of the patients remained positive for IgA for up to five months post infection.
Maximum levels of IgA were found at a later date post-infection than the maximum




























































Figure 1. Positivity rates of IgM and IgA antibodies to poliovirus type 3 in poliomyelitis
patients. Results are from consecutive serum samples from 15 patients with poliomyelitis
collected during the 1992-1993 outbreak in The Netherlands.
IgA in IPV-vaccinated children
Poliovirus-specific-IgA was found in 4.5%, 7.3% and 5.6% of young children (4-12
years) for serotypes 1, 2 and 3 [Figure 2]. No correlation was found between the total
number of IPV doses received and the number of children with detectable IgA levels
(results not shown). Eighteen percent of the older schoolchildren (13-15 years) had
IgA antibodies to serotype 1, whereas the seroprevalence of IgA to serotypes 2 and 3
was low (3.3% and 2.3 % respectively) [Figure 2].







































Figure 2. Seroprevalence of IgA antibodies to poliovirus type 1, 2 and 3 in different age
groups of IPV vaccinated persons in The Netherlands (group I-III) and in persons born before
the vaccination programme (group IV). The populations were I) 4-12 year old school children
(n=177), II) 13-15 year old school children (n=123), III) IPV vaccinated blood donors (n=66,
labelled 18-65 years) and IV) 52-85 year old persons without previous vaccination (n=54). *=
significant (p<0.05) compared to 4-12 year old schoolchildren, **= significant (p<0.01)
compared to schoolchildren and blood donors.
IgA levels in IPV-vaccinated healthy adults
IgA antibodies were found in 21.2%, 27.3% and 12.1% of healthy adult blood donors
for serotypes 1, 2 and 3 respectively [Figure 2]. The seroprevalence of poliovirus
serotype 1- and serotype 2-specific IgA was significantly higher (c2, p<0.05) in adults
than in the young schoolchildren (4-12 years). Antibodies to serotypes 2 and 3 were
significantly more prevalent (c2, p<0.05) in the blood donors than in the older
children (13-15 years).
IgA levels in OPV-vaccinated healthy adults
IgA was found more frequently in the OPV-vaccinated Belgian blood donors (33.8%,
32.3% and 32.3% for serotypes 1, 2 and 3 respectively) than in age-matched IPV-
vaccinated donors from The Netherlands as mentioned (21.2%, 27.3% and 12.1% for
serotypes 1, 2 and 3 respectively). The difference was only significant for serotype 3
(c2, p<0.05).
IgA antibodies in elderly adults pre- and post-IPV vaccination
Before IPV vaccination, the group of older subjects (52-85 years old, n=53) had
neutralisation titers (³ 1:8) to serotypes 1, 2 and 3  (87%, 83% and 79% respectively).
Four weeks after vaccination, 96% of these subjects had protective levels of
neutralising antibodies for all three serotypes. Only two subjects did not develop
neutralising antibodies to serotype 3 after the IPV booster. Before IPV vaccination,
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40%, 49% and 30% of the subjects had detectable IgA against serotype 1, 2 and 3
respectively [Figure 2], In most cases the ELISA absorbance values were low, and











































Weeks after IPV vaccination
Figure 3. Levels of IgM, IgA and sIgA before and after vaccination with IPV in an older
population. Dots indicate median values in each group. Error bars indicate upper (75 %) and
lower (25 %) quartiles.
After the IPV booster, a strong increase in IgA levels occurred within one week for
serotype 1 (93% of the subjects), serotype 2 (94% of the subjects) and serotype 3
(83% of the subjects). A booster response to all three serotypes was found in 77% of
the subjects [Figure 3]. Four weeks following IPV vaccination, three subjects (6%)
had no detectable IgA antibody to serotype 1 poliovirus, one subject (2%) had no
detectable IgA antibody to serotype 2 and seven subjects (14%) had no detectable IgA
antibody to serotype 3. All IgA positive serum samples were also positive in the
neutralisation assay.
Secretory IgA levels in elderly adults pre- and post-IPV vaccination
Only a small fraction of the older subjects had detectable secretory-IgA against
poliovirus serotype 1 (8.3%), serotype 2 (14.6%) and serotype 3 (10.4%) before IPV
vaccination. In all cases except one (serotype 2), OD values were low (< 2 times the
cut-off value). One week after the administration of one dose of IPV, 75%, 87%, and
74% of the subjects reacted with a rapid increase in sIgA in serum for serotype 1, 2
and 3 respectively [Figure 3]. Levels of sIgA remained high until at least four weeks
after the administration of IPV. All serum samples tested in the sIgA assay were IgM-
negative.
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Discussion
We studied serum IgA responses after poliovirus infection or vaccination in different
age groups of persons vaccinated with IPV in The Netherlands. We developed ELISA
assays to measure poliovirus-specific (secretory) IgA circulating antibodies. The
specificity of both IgA ELISAs was high for all three serotypes (99% to 100%). A
positive reaction could only be blocked with homologous virus indicating that cross-
reactivity with other poliovirus serotypes, and probably other enteroviruses as well,
did not occur.
IgA antibodies to the other two serotypes were also detected in four out of the 15
persons from the group of poliomyelitis patients from the 1992/1993 serotype 3
epidemic in The Netherlands, suggesting cross-reactivity. A more likely explanation,
however, is that this was caused by contact with the OPV virus offered during the
epidemic. The sensitivity was determined by testing a group of poliomyelitis patients,
and was rather low (81% to 90%). This may be explained by a short duration of the
IgA response that may have been missed during the infrequent sampling schedule.
The sensitivity of the ELISAs appears sufficient for the study of poliovirus immunity
in well-defined populations.
IgA in the group of poliomyelitis patients peaked, on average, at four weeks after the
onset of paralysis, and was back at low levels in the majority of persons after three
months. It was striking that the poliovirus serotype 3-specific IgA antibodies persisted
in approximately one third of the patients beyond five months post infection,
confirming data from the literature [12]. Persisting IgA levels suggest a continuous or
repeated antigenic stimulus of the immune system, however, there is little or no
evidence of persistent poliovirus infection in contrast to other enterovirus infections.
An alternative explanation might be the retention of viral antigen in dendritic cells in
the bone marrow [1,18].
We examined sera from different age groups for IgA antibodies. The seroprevalence
of poliovirus-specific IgA was low (5%-7%) in young schoolchildren (4-12 years),
and we found no increase after more dosages of IPV. A drawback of this study is that
the sera used for these experiments were not collected immediately after vaccination,
and IgA induced by IPV could have disappeared from the circulation at the time of
testing. The low number of fully IPV-vaccinated children that tested positive for IgA
shows that IPV may induce IgA antibodies, but only in a small proportion (5%-7%),
and that IgA may not be present in serum for an extended period of time. In keeping
with our findings, it has been described that IPV vaccination in children can induce
sIgA in saliva after at least three dosages, but only in a minority of vaccinated
children (9%) [3,18,19]. This is not a result of the incapability of children to produce
sIgA, since children at six months of age in Pakistan produced levels of salivary IgA
similar to those in adults [3].
Serotype 2- and serotype 3-specific IgA was less prevalent in the older children than
in the group of younger children, a finding that may reflect waning immunity. The
higher seroprevalence rates of IgA to serotype 1 poliovirus in the older schoolchildren
is most likely explained by the persistence of IgA following infection with the
serotype 1 wild-type poliovirus strain during the 1978 epidemic [17]. After 1978, wild
poliovirus type 1 was not found in this community, and any vaccine would have
included all three serotypes. The older schoolchildren may have been infected in their
first few years of life. In addition, healthy adults had a significantly higher
seroprevalence of IgA for serotypes 1 and 2 than did IPV vaccinated children. This
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finding is not merely explained by cohort effect, as the difference was also seen when
blood donors born before the start of the national vaccination program were excluded
from the data analysis.
This finding strongly suggests that additional stimulation of the immune response to
poliovirus with wild-type poliovirus or live vaccine strains has occurred. Similarly, an
unvaccinated population of 52 to 85 year old persons had the highest seroprevalence
of IgA to all three serotypes compared to all other age groups. All IgA levels found in
this group must have been induced by infection with live virus (vaccine or wild type).
This may have occurred during childhood when poliovirus was still endemic in The
Netherlands, during holidays in OPV-countries, or through the importation of wild or
vaccine-derived polioviruses into The Netherlands. However, there is no evidence for
the endemic circulation of wild or vaccine virus in The Netherlands during the period
1979-1991 [16].
Interestingly, parenterally administered IPV in elderly, non-immunized persons was
able to induce strong memory IgA and secretory IgA responses. Induction of memory
secretory IgA responses by a parenterally administered inactivated vaccine has also
been described for the influenza virus [2,10], pseudomonas aeruginosa and
meningococci [6,9]. The authors postulated that the cause of these responses is most
likely to be previous mucosal priming with wild type infection (e.g. with the influenza
virus), as may have been the case for live poliovirus in the population that we studied.
The rapid immune response in our own experiments combined with the lack of
induction of poliovirus-specific IgM also suggests a secondary response and shows
that parenteral poliovirus vaccines can induce a secretory IgA response in persons
previously exposed to live poliovirus. It remains to be determined how sIgA
responses in serum correlate to sIgA at mucosal sites and to protection, and whether
IPV can also boost sIgA in persons without previous mucosal infection. Experiments
are underway to examine these relations.
In summary, we have shown that IgA antibodies to poliovirus are present in fully
IPV-vaccinated children, but only in a small proportion, whereas the seroprevalence is
significantly higher in adult IPV vaccinees. This suggests that most of the IgA present
later in life in an IPV-vaccinated population was induced by continuous or additional
exposure to live virus strains (wild or vaccine) and/or due to the persistence of IgA. In
addition, we have shown that parenteral IPV was able to boost secretory IgA
responses in a naturally exposed elderly population, suggesting a link between the
systemic and mucosal immune system.
In the near future, poliomyelitis due to wild-type infection will be eradicated and the
circulation of live polioviruses will decrease. An important question remains: Will an
IPV-vaccinated population be able to mount a mucosal (booster) immune response
under these circumstances? Our future work will focus on the capacity of parenteral
IPV to prime for mucosal memory responses and to provide protection against virus
excretion.
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The inactivated poliovirus vaccine (IPV) is used for protection against poliomyelitis
in The Netherlands. It is not clear, however, whether IPV vaccination can lead to
priming of the mucosal immune system and the induction of IgA. We have previously
shown that significantly fewer children than adults have circulating IgA in this IPV-
vaccinated population, suggesting that at least part of the IgA found in the older
population in The Netherlands is induced by infections and is unrelated to IPV
vaccination. It has also been demonstrated that IPV vaccination is able to induce
strong memory IgA responses in the serum of persons who have been naturally
exposed to live (wild-type) poliovirus. This has led to the hypothesis that IPV
vaccination is able to induce poliovirus-specific IgA at mucosal sites in persons who
have been previously primed with live (wild or vaccine) poliovirus at mucosal sites.
To test this hypothesis, the kinetics of the IgA response in serum and saliva after IPV
vaccination were examined in persons previously vaccinated with oral poliovirus
vaccine (OPV) or IPV. ELISA and ELISPOT-assays were used for the detection of
poliovirus-specific IgA responses. In addition, B cell populations were separated on
the basis of the expression of mucosal (a4b7 integrin) and peripheral (L-selectin)
homing receptors. Parenteral IPV vaccination was able to boost systemic and mucosal
IgA responses in previously OPV-vaccinated persons only. None of the previously-
vaccinated IPV recipients responded with the production of IgA in saliva. In
agreement with this finding, a large percentage of the poliovirus-specific IgA-
producing lymphocytes detected in previous OPV recipients expressed the a4b7
integrin. It is concluded that IPV vaccination alone is insufficient to induce an
effective mucosal IgA response against poliovirus and that, conversely, mucosal IgA
responses measured after IPV vaccination are most likely the result of previous
mucosal priming with live poliovirus. In mucosally- (OPV-) primed individuals,
however, booster vaccination with IPV leads to a strong mucosal IgA response.
Introduction
Poliomyelitis has been effectively controlled through the use of two different
vaccines; the inactivated poliovirus vaccine (IPV) and the attenuated poliovirus
vaccine (OPV) [26]. Mucosal immunity protects from (re)infection and is essential for
the reduction of poliovirus circulation in the population [9,21,22]. The induction of
mucosal immunity is, therefore, of particular importance for the poliomyelitis
eradication program because both poliovirus-induced paralysis and poliovirus
circulation must cease completely in order to reach the target of a polio-free world.
Whether wild-type poliovirus can remain circulating in vaccinated populations (silent
circulation) is an important question for the eradication program. In theory, silent
circulation is possible in IPV-vaccinated populations because intramuscular
vaccination with inactivated poliovirus (IPV) probably induces little or no secretory
IgA (sIgA) at mucosal sites. Several studies, however, indicate that some degree of
mucosal immunity can be measured in IPV vaccinees, albeit less than in people who
have been vaccinated with the oral poliovirus vaccine (OPV) or infected with wild-
type virus [4,5,9,11,23]. Most information comes from studies that were conducted
during periods when poliovirus was still endemic or in regions where OPV was also
used. The results of these studies, therefore, are likely to be confounded by additional
priming of the (mucosal) immune system through infection with live poliovirus
(vaccine or wild-type). Some of the more recent studies have also included IPV-
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vaccinated subjects recruited from endemic regions [5,16]. It is still unclear whether
IPV vaccination alone is able to induce mucosal immunity and is responsible for the
induction of secretory IgA in saliva and/or stool samples.
We have previously shown that IPV vaccination can induce strong memory IgA
responses in the serum of persons who have been naturally exposed to live (wild-type)
poliovirus [12]. An age-dependent increase in the presence of IgA in the circulation of
the IPV-vaccinated population in The Netherlands has also been described, and this
increase can not be explained by IPV vaccination alone [12]. Based on these results,
we have postulated that a memory IgA response after IPV vaccination is dependent on
previous mucosal infection with live poliovirus (vaccine or wild-type).
To test this hypothesis, both IPV- and OPV-recipients were given a booster
vaccination with one dose of IPV. The group of OPV recipients served as a model for
previous mucosal priming with live poliovirus. The induction of poliovirus-specific
IgA was measured in the plasma, saliva and stool samples of the volunteers.
Poliovirus-specific IgG and IgA antibody-producing cells isolated from the
circulation were enumerated by ELISPOT assays. The homing potentials of the
poliovirus-specific IgG- and IgA-producing lymphocytes found in the circulation
were also examined to determine their final destination.
Materials and Methods
Vaccine recipients and booster immunisation
Fourteen IPV-vaccinated volunteers from The Netherlands (average age 25.8, range
20-41 years) and 11 OPV-vaccinated volunteers (average age 32.5, range 25-44 years)
from various countries using OPV in their national programs were enrolled in the
study. Most OPV recipients were from countries in which circulation of wild-type
poliovirus has been absent or at low levels for some time (Canada, Germany,
Belgium, Italy, New Zealand, Austria, Spain and Curaçao). One OPV recipient was
from Morocco, where wild-type poliovirus has been detected as recently as 1995.
All volunteers were injected intramuscularly with a standard dose of the inactivated
poliovirus vaccine (Diphtheria-, Tetanus-, Poliomyelitis vaccine, RIVM, Bilthoven,
The Netherlands) containing 40, 4 and 7.5 D-antigen units for serotypes 1, 2 and 3
respectively. This vaccine is also used in the regular immunisation program in The
Netherlands, where a total of six IPV vaccinations are given at 3, 4, 5 and 12 months,
and at 4 and 9 years of age. Blood specimens were collected before booster
vaccination and at 3, 7 and 28 days post-vaccination and were immediately processed.
Saliva samples were collected at each of the first 10 days after vaccination, and every
week thereafter until 8 weeks post-immunisation. Three stool specimens (week 0, 1
and 2) were examined for poliovirus-specific antibodies. Stool and saliva samples
were stored at –20°C until use.
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Blood samples were collected in containers using EDTA as an anticoagulant. The
blood samples were layered on an equal volume of ficoll (Histopaque, Sigma,
Zwijndrecht, The Netherlands). After centrifugation (30 min, 400 x g) the
lymphocyte-rich interphase was removed by pipette. The plasma was collected and
stored at –20°C until testing in the ELISA assays was done. Cells were washed twice
in RPMI/10% FCS (10 min, 250 x g), counted and adjusted to the required
concentration.
Separation of homing receptor -positive and -negative cell populations
The separation of the lymphocytes into homing receptor-positive and -negative
populations has been described by Kantele et al. [15]. Cells were separated on the
basis of the expression of the integrin a4b7 which mediates trafficking to the intestine
and intestinal lymphoid tissues, and L-selectin (Chemicon, Temecula, USA), which
mainly mediates trafficking to the peripheral lymph nodes [1,10,28]. Cells (107
cells/ml) were incubated with 1 µg/ml monoclonal antibody to L-selectin or with 2
µg/ml monoclonal antibody to a4b7 (Act-1, kindly provided by Leukosite, Ambridge,
USA, and Dr. Lazarovitz) for 30 minutes at + 4°C under rotation in a volume of 1 ml
medium. Cells were washed three times and incubated with 2*107 magnetic beads
coated with sheep-anti-mouse IgG (Dynal M-450, Oslo, Norway). The beads with the
attached cells were separated from the receptor-negative population through the
application of a magnet. The beads were washed once and the separation was
repeated. The receptor positive cells attached to the beads were suspended in medium.
Both positively- and negatively-selected cell populations were used in ELISPOT
assays.
FACS analysis
The composition of the negatively-selected cell populations was examined after cell
separation by FACS analysis. Cells were incubated on ice for 30 minutes with
primary antibody to L-selectin or a4b7-integrin (Act-1). After incubation, the cells
were washed 3 times with 1% BSA in PBS and incubated on ice for 30 minutes with
FITC-conjugated goat anti-mouse conjugate (Cappel, Aurora, USA). Cells were
washed and analysed using FACScan (Becton Dickinson, San Jose, USA). The
average purity of the negatively-selected cell population after separation was 95% and
97% for L-selectin, and 4b7 respectively.
ELISPOT-assay
Microtiter plates were coated with an optimal dilution in carbonate buffer of bovine
anti-poliovirus serotype 1, 2 or 3 (RIVM, Bilthoven, The Netherlands) and were
incubated overnight at + 4°C. The wells were then saturated with 10% fetal calf serum
(FCS) in RPMI for 1 hour at 37°C. Antigen was added in a concentration of 40 to 120
DU/ml inactivated poliovirus and incubated for 2 hours at 37°C. Plates were washed
four times with PBS supplemented with 0.5% Tween. Two-fold serial dilutions of the
PBMC in a volume of 100 µl starting at 106 cells/ml were incubated for 4 hours,
allowing the lymphocytes to secrete antibodies. Plates were washed and the antibodies
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bound to the viral antigen on the plate were detected by alkaline phosphatase-
conjugated IgG or IgA class-specific immunoglobulins (Sigma, Zwijndrecht, The
Netherlands). Plates were incubated for 2 hours at 37°C. After washing the plates,
substrate (5-bromo-4-chloro-3-indolyl phosphate) in a concentration of 0.65 mg/ml
was diluted in 2-amino-2methyl-1-propanol substrate buffer with agarose of 40°C,
then added to the wells and allowed to harden. Antibody-producing cells were visible
as blue spots and were enumerated under a microscope allowing the total number of
antibody-producing cells per 106 cells to be calculated. Cells were cultured in the
absence of the poliovirus antigen as a control.
Poliovirus-specific total IgA, IgA1 and IgA2-ELISAs (plasma, saliva and stool)
The IgA ELISA was performed as described [12]. The presence of poliovirus-specific
IgA was determined in plasma, saliva and stool samples. Plasma samples were
inactivated (30 minutes at 56°C) before use in the IgA-ELISA, and were depleted of
IgG antibodies with Quik-Sep (Isolab, Mechelen, Belgium) according to the
manufacturer’s instructions to prevent possible inter-isotype competition. Saliva
samples were centrifuged (10 minutes, 3500 rpm) and inactivated for 30 minutes at
56°C. A 10% w/v suspension of the stool samples was added to the IgA ELISA at a
1:2 dilution. ELISA assays were performed with IgA1- and IgA2-specific conjugates
(Southern Biotechnology Associates, Uithoorn, The Netherlands) to determine the
subclasses of poliovirus-specific IgA. Optimal dilutions of reagents were determined
by checkerboard titration. Positive and negative control serum samples were included
in all IgA assays.
Poliovirus-specific secretory antibody capture-ELISA
A capture-ELISA was used as described to determine whether IgA detected in plasma
samples after IPV vaccination was also present in its secretory form [12]. Briefly,
microtiter plates were coated with a monoclonal antibody against the secretory
component (Sigma, Zwijndrecht, The Netherlands) by overnight incubation at 4°C in
carbonate buffer. Plates were blocked with 5% Blotto (Pierce, Oud Beijerland, The
Netherlands). Plasma dilutions (1:50) were added and the plates were incubated for
1.5 hours at 37°C. Inactivated poliovirus was added and bound antigen was detected
with horseradish-peroxidase-labelled serotype-specific monoclonal antibody (1 hour,
37°C). Tetramethylbenzidine (TMB) was used as a substrate (0.1 mg/ml) in 0.11 M
sodiumacetate buffer, and the reaction was stopped after 30 minutes with 2 M H2SO4.
Poliovirus-specific subclass and total IgG ELISA (saliva and plasma)
Saliva and serum samples were tested for the presence of poliovirus-specific IgG
antibodies. Assays were performed as described for the IgA ELISA but with anti-
human-IgG-alkaline phosphatase labelled conjugate or with biotin-labelled antibodies
to the different subclasses of IgG (IgG1, 2, 3 and 4; Sigma, Zwijndrecht, The
Netherlands). Optimal dilutions of reagents were obtained by checkerboard titration.
Avidin conjugated with alkaline phosphatase was added to the plates which were then
incubated for 1 hour at 37°C. The plates were washed, and 100 µl of p-
nitrophenylphosphate at a concentration of 1 mg/ml in 0.1 M glycine buffer was
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added to each well. The plates were read at 405nm after incubation at room
temperature for 30 minutes.
Poliovirus-Binding Inhibition assay (PoBI)
The PoBI was performed as described to determine the poliovirus-specific antibody
titer in the plasma samples [13]. The reciprocal of the first serum dilution that was
positive in the inhibition test was taken as the titer of the test sample.
Poliovirus-specific IgM capture-ELISA
The IgM-ELISA was performed as described [20]. A positive and a negative control
serum were examined in each assay.
Statistical Methods
Student’s t-tests were performed to determine the significance of the difference
between IPV and OPV recipients. P-values of <0.01 were considered significant.
Results
Poliovirus-specific IgA- and IgG-producing cells in volunteers before and after
IPV booster vaccination.
The number of poliovirus-specific IgA-and IgG-producing cells in the circulation was
determined for all three serotypes of poliovirus at 0, 3, 7 and 28 days [Figure 1]. Both
IPV- and OPV-vaccinated subjects responded with IgG-producing cells that were only
detectable at day 7 after booster vaccination with IPV [Figures 1A and 1B]. High
numbers of IgA-producing cells were detected in OPV-vaccinated persons 7 days
after vaccination [Figure 1D]. In contrast, none of the IPV recipients had IgA-
producing cells to serotypes 1 and 2 and only one IPV-vaccinated subject responded
with 230 serotype 3-specific IgA-producing cells/106 cells at day 7 [Figure 1C]. No
poliovirus-specific IgG- and IgA-producing cells were detected in either group at 0, 3
or 28 days after booster vaccination.
The L-selectin and a4b7 positive and negative cell populations were tested in
serotype 3-specific ELISPOT assays [Figure 2]. The majority (77.3%) of the
poliovirus-specific IgA-producing cells detected 7 days after booster vaccination in
the OPV-recipients expressed the a4b7-integrin on their surface [Figure 2A]. A
median level of 2744 and 808 poliovirus-specific IgA-producing cells/106 cells were
measured for a4b7 integrin-expressing and non-expressing cells respectively.
Poliovirus-specific IgA-producing cells were detected in both the L-selectin-positive
and -negative populations in the OPV vaccinated group [Figure 2B]. Thirty-nine
percent of the poliovirus-specific IgA-producing cells expressed L-selectin on their
surface. There was no significant difference between the IPV and OPV recipients in
the proportion of poliovirus-specific IgG-producing cells expressing the a4b7 integrin
(72.3% versus 72.6%, data not shown). However, 80.9% of the poliovirus-specific
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IgG producing cells expressed L-selectin in the IPV-vaccinated group while only
46.5% tested positive for L-selectin in the OPV recipients (data not shown).
Figure 1. Poliovirus-specific IgA and IgG producing cells in the circulation at 0, 3, 7 and 28
days after an IPV booster vaccination in previously IPV-and OPV-vaccinated individuals
determined by ELISPOT assays. Horizontal lines indicate the median values.
Figure 2. Expression of the L-selectin and a4b7 integrin homing-receptors on the poliovirus-
specific IgA-producing cells in the circulation 7 days after an IPV booster vaccination in
previously IPV- and OPV-vaccinated individuals. Horizontal lines indicate the median values.
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Figure 3. Poliovirus-specific IgA in the saliva after an IPV booster vaccination of previously
IPV-and OPV-vaccinated individuals. Results are expressed in median values and the 25%
and 75% percentiles of the ratio of positive reaction in ELISA readings in the presence of
antigen divided by the ELISA readings in the absence of antigen (P/N ratio).
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Poliovirus-specific IgA in saliva
A significant difference (p=<0.01) was seen between OPV and IPV recipients in the
poliovirus-specific salivary IgA response for the three serotypes after the IPV booster
vaccination [Figure 3]. Nine out of eleven OPV recipients developed a salivary IgA
response to all three serotypes of poliovirus after the IPV booster vaccination. The
poliovirus-specific IgA appeared in the saliva within five to six days after the booster
vaccination. None of the IPV-vaccinated volunteers (n=14) responded with
poliovirus-specific IgA in the saliva [Figure 3].
Poliovirus-specific IgA in stool
Poliovirus-specific IgA to all three serotypes was detected in the stool samples of
three out of nine of the OPV-vaccinated subjects. A mucosal IgA response was not
detected in any of the IPV-vaccinated subjects’ stool samples. This difference was not
significant (data not shown).
Poliovirus-specific IgA in plasma
Two subjects in the OPV group had detectable IgA to all three serotypes in their
circulation before the IPV booster vaccination was given [Figure 4B], and one subject
in the IPV group had detectable poliovirus-specific IgA to serotypes 2 and 3 at day 0.
There was a clear increase in levels of circulating plasma IgA to all three serotypes in
the OPV-vaccinated group at day 7 after the IPV booster vaccination, and the
response remained elevated up to day 28 [Figure 4]. IgA responses to all three
serotypes of poliovirus were also detected in the IPV-vaccinated group, but the levels
were significantly lower than those observed in the OPV recipients (p= <0.01).
Poliovirus-specific IgA1 and IgA2 in plasma
Poliovirus-specific antibodies were clearly present in both IgA1 and IgA2 subclasses
in the OPV recipients [Figure 4D & 4F]. IgA responses in the IPV recipients were
seen at very low levels and appeared to be mainly of the IgA1 subclass. No
poliovirus-specific IgA2 was detected in the majority of IPV recipients.
Poliovirus-specific secretory antibodies in plasma
The IPV and OPV recipients also differed in the induction of poliovirus-specific
antibodies bound to the secretory component (SC) in their circulation [Figure 5].
Poliovirus-specific secretory antibodies appeared in 7 out of 10 OPV recipients for all
three serotypes. Such responses were absent in the IPV recipients for serotype 1, and
only 2 out of 11 IPV recipients had detectable poliovirus-specific secretory antibodies
for serotype 2 and 3 [Figure 5A]. In all cases, the secretory antibody responses were
at low levels and of short duration, with an apparent peak at day 7.
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Figure 4. The induction of poliovirus-specific IgA and subclass IgA1 and IgA2 in the plasma
samples after an IPV booster vaccination in previously IPV- and OPV-vaccinated individuals
at 0, 3, 7 and 28 days after IPV booster vaccination. Horizontal lines indicate the median
values.
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Figure 5. Induction of poliovirus-specific antibodies in association with secretory component
after an IPV booster vaccination in previously IPV- and OPV-vaccinated individuals at 0, 3, 7
and 28 days after IPV booster vaccination. Horizontal lines indicate the median values.
Poliovirus-specific (subclass) IgG in plasma and saliva
In general, the total IgG response in the plasma samples from both groups was not
significantly different and consisted mainly of the IgG1 subclass [Figure 6]. However,
the IgG3 subclass response was more prominent in the IPV group compared to the
OPV recipients and this difference was significant (p<0.05) for serotypes 1 and 3 at
day 7 and day 28 after vaccination [Figure 6E and 6F]. A low level IgG2 response
was induced by the IPV booster vaccination in several individuals from both groups
(data not shown). No clear response was seen in IPV and OPV recipients for IgG4 for
all serotypes (data not shown). No poliovirus-specific IgG was seen in the saliva after
IPV booster vaccination in most of the IPV and OPV recipient groups. However, two
IPV recipients and one volunteer from the OPV group responded with an IgG
response in the saliva to all three serotypes (data not shown).
Poliovirus-Binding Inhibition assay (PoBI)
At the start of the study, the median levels of PoBI titers were generally higher in the
IPV-vaccinated group than in the OPV recipients. This difference was significant for
serotype 3 (p<0.01). However, the OPV recipients responded with a similar increase
in PoBI titers after IPV vaccination and reached the same levels at day 28 (data not
shown).
Polio-specific IgM in plasma.
Low positive IgM responses only were detected in recipients from both study groups
at 7 and 28 days after booster vaccination. Three, two and four out of 11 volunteers in
the IPV-vaccinated group had an IgM response to serotype 1, 2, and 3 respectively.
Three, five and five persons out of 10 volunteers in the OPV-vaccinated group had an
IgM response for serotype 1, 2 and 3 respectively. No significant differences were
detected in IgM responses between the OPV recipients and IPV recipients (data not
shown).
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Figure 6. Induction of total IgG, IgG1, and IgG3 after an IPV booster vaccination of previously
IPV and OPV recipients at 0, 3, 7, and 28 days after IPV booster vaccination. Horizontal lines
indicate the median values.
Discussion
Although low levels of mucosal immunity have been found after IPV vaccination in
previous studies, these responses have been less effective in reducing viral shedding
after a challenge with OPV than those observed after OPV vaccination
[4,5,9,11,16,23]. This study was conducted in order to determine mucosal immune
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responses following IPV vaccination in a country with almost no circulating
poliovirus. Under these circumstances, it is clear that IPV vaccination alone is not
sufficient to induce mucosal IgA. From this and previous work we conclude that the
previously reported mucosal responses after IPV vaccination are more likely to be the
effect of previous mucosal priming with live viruses than the effect of IPV
vaccination alone. It remains to be determined whether or not IPV vaccinees (in the
total absence of a mucosal IgA response) are partially protected in challenge
experiments. Reduced virus shedding in IPV recipients after challenge with OPV has
been reported previously, but again, it is unclear in these experiments whether
poliovirus immunity was solely induced by IPV vaccination as opposed to a mixed
immunisation of IPV combined with mucosal infection [11,21,23].
The poliovirus-specific IgG levels detected in the saliva of IPV recipients were low or
absent, suggesting that salivary IgG does not play a role in protection from mucosal
infection with poliovirus. IgG is thought to enter the mucosal secretions non-
specifically through paracellular transport. It remains to be investigated whether or
not circulating IgG is able to exert an influence on protection to a mucosal poliovirus
challenge. It has been postulated that a critical level of specific serum IgG may be
sufficient to protect against infectious diseases by inactivating the inoculum of the
pathogen [25].
Assuming that the absence of mucosal IgA reflects a lack of mucosal protection, our
observation may have implications for the poliomyelitis eradication program in The
Netherlands. In the absence of an efficient mucosal barrier, IPV recipients will remain
sensitive to poliovirus infection. These infections will go unnoticed because fully-
vaccinated persons will not develop any symptoms of disease. Under these
circumstances, IPV recipients will contribute to the (continuous) circulation of
poliovirus. This poses a special risk to the religious communities with low vaccine
coverage that presently exist in The Netherlands. Despite high national vaccine
coverage, epidemics of poliomyelitis within these groups occurred in 1978 and 1992
[2,6,24,27]. During the advancing stages of poliomyelitis eradication, and taking into
account a decrease in the incidence of the mucosal infection of IPV recipients by live
poliovirus, this effect is likely to be even more pronounced, resulting in the waning of
presently existing mucosal immunity in the general population.
Parenteral IPV vaccination induced a strong and rapid IgA response in previously
OPV-vaccinated persons both at mucosal sites and in the circulation. Similar memory
IgA responses in the circulation after IPV vaccination were detected in a group of
non-vaccinated but naturally exposed persons [12]. Induction of memory sIgA
responses by parenterally-administered inactivated vaccines has also been described
for influenza virus [3,19], Pseudomonas aeruginosa, and meningococci [8,18]. Natural
infection with these agents is very common in such cases, and the authors postulate
that the memory IgA response most likely resulted from previous mucosal infection
with the wild-type virus or bacteria, based on the dogma that mucosal antigen
presentation is required for an effective mucosal immune response.
The mechanism by which inactivated parenteral vaccination can re-stimulate the
mucosal IgA responses is unknown. The memory IgA-producing cells detected in our
experiments have most likely been originally primed at mucosal sites. IPV is applied
intramuscularly, therefore the peripheral lymph nodes are theoretically the first
lymphoid location for antigen presentation to memory cells [29]. Expression of L-
selectin (indicating homing to peripheral lymph nodes) on poliovirus-specific IgG-
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and IgA-producing cells was demonstrated in this study. The memory lymphocytes
will proliferate after re-stimulation and leave the peripheral lymph nodes. A large
proportion (73%) of the circulating poliovirus-specific IgA-producing cells expressed
the a4b7 mucosal homing receptor, indicating a preference for homing to mucosal
surfaces. This was underscored by the induction of poliovirus-specific IgA in saliva.
At least a proportion of the poliovirus-specific IgA-producing cells in this experiment
expressed both the a4b7 integrin and L-selectin on their surface. It is known that
some homing receptors are expressed continuously while others are induced by local
activating signals acting on both circulating and local cells [1]. The final combination
of homing receptors on the cells’ surface is likely to account for the regional
preference of the activated cells. The presence of memory cells that express both the
L-selectin and a4b7 homing receptors are an ideal immune surveillance mechanism
for the control of infections both at the systemic and mucosal level.
The poliovirus-specific subclass responses of IgA and IgG were determined in order
to investigate whether there was a qualitative and quantitative difference in the
humoral immune response after IPV booster vaccination in previously IPV- and OPV-
vaccinated persons. Poliovirus-specific IgA2 in the circulation was clearly present in
the OPV recipients and might be derived from lymphocytes that were originally
primed at mucosal sites. The presence of poliovirus-specific IgA2 in the plasma might
serve as a systemic marker for mucosal memory rather than the presence of total
poliovirus-specific IgA, since an IgA1 response (albeit a small one) was also seen in
some of the IPV recipients.
We detected an IgG1 and IgG3 subclass response before and after IPV booster
vaccination in both the OPV and IPV recipients [Figure 7]. Similar results were
reported in poliomyelitis patients and for other enteroviral antigens [14,30]. However,
the IgG3 response in the OPV recipients was significantly lower than in IPV
recipients in this study. These results might indicate a difference in preference for an
IgG1 switch over an IgG3 switch after mucosal priming with OPV compared to
systemic vaccination with IPV. No clear IgG4 response was observed and only a few
individuals responded with IgG2 poliovirus-specific antibodies. Mechanisms for the
observed differences remain to be investigated.
Not much is known about the induction and presence of circulating secretory IgA.
Immunoassays indicate that secretory IgA can be detected at relatively low levels (+/-
10µg/ml) in serum [7,17]. This study detected poliovirus-specific secretory IgA after
booster vaccination with IPV in previously OPV-vaccinated recipients. The response
was at low levels and decreased rapidly. The biological relevance of this finding is
speculative and remains to be investigated, although we speculate that it represents an
overload of the secretory system.
Vaccination with OPV introduces live virus into the environment and must therefore
cease completely in the future. This study has demonstrated that IPV booster
vaccinations are able to maintain a high level of mucosal IgA response for years after
initial vaccination with OPV. A combination schedule of OPV and IPV vaccination
could serve as a powerful tool in the final stages of the eradication program.
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Lessons from diagnostic investigations of
poliomyelitis patients and their direct
contacts for the present surveillance of
acute flaccid paralysis






One of the key strategies for the global eradication of poliomyelitis is the virological
investigation of stool samples from all cases of acute flaccid paralysis (AFP) to
exclude poliovirus as a possible cause. However, adequate virological investigation of
the stool specimens from these patients is carried out in fewer than the required
number of cases, especially in industrialised countries. Poliomyelitis cannot be
excluded in all of these cases. Other diagnostic assays using both immunological and
molecular biological methods have been developed within the last decade for the
detection of poliovirus infection. Clinical specimens from the 1992/93 poliovirus
serotype 3 outbreak in The Netherlands provided an opportunity to examine the
potential of the various methods for the diagnosis of poliomyelitis. The virus isolation
rate in poliomyelitis patients was maximal (89.6%) during the first two weeks after
the onset of paralysis and then dropped sharply to 18.6%. In contrast, a high
percentage of the patients tested positive for serotype 3-specific IgM (93.3%) and IgA
(87.1%) in the early phase of the infection and remained positive up to eight weeks
after the onset of paralysis. While the serotype 3-specific IgM rate dropped to 20% at
8 weeks after infection, the poliovirus-specific IgA persisted in many patients (56.7%)
for more than 8 weeks after infection and is therefore less suitable for the diagnosis of
recent infections. The use of virus isolation would have correctly identified only
54.9% of AFP cases in the theoretical event that all of these cases were due to
poliovirus infection. The identification rate would have been increased to 92%
through the use of the poliovirus-specific IgM ELISA. Virus isolation from stool
specimens will remain the standard diagnostic method. The speed and ease of
performance of the IgM ELISA, however, could allow it to serve as an important
additional tool for the rapid diagnosis of poliomyelitis. Moreover, the IgM ELISA
may facilitate the resolution of AFP cases when stool investigation has been less than
adequate or in cases analysed late after the onset of disease.
Introduction
In 1988, the World Health Organisation (WHO) launched an initiative to eradicate
poliomyelitis by the year 2000 [10]. One of the key strategies for the global
eradication of poliomyelitis is the virological investigation of stool samples from all
cases of acute flaccid paralysis (AFP) to identify poliovirus as a possible cause [29].
Acute flaccid paralysis (AFP) is characterised by the rapid onset of muscle weakness
in the extremities, or in some cases the muscles involved in respiration and
swallowing. The maximum severity of symptoms is apparent within one to ten days
post-onset [30]. AFP can have numerous other causes apart from poliovirus infection,
including infections with other enteroviruses, acute myelopathy, peripheral
neuropathy (such as the Guillain-Barré Syndrome) and neuromuscular transmission
disorders [30].
The incidence of AFP in the absence of poliomyelitis is estimated to be at least one
case per 100,000 children younger than 15 years of age [3]. The timely collection of
adequate stool samples from AFP cases is considered crucial for viral detection, and
the collection of two samples 48 hours apart within 14 days after onset of paralysis is
used by the WHO as performance criteria for the quality of the AFP surveillance [30].
However, compliance with these criteria is limited. This is especially true in
industrialised countries where, because of the absence of poliomyelitis cases,
clinicians do not always recognise the need for intensive AFP surveillance [10].
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Both our laboratory [15,20] and other groups [11,14,21,22,25,32] have developed
poliovirus serotype-specific IgM- and IgA-enzyme-linked immunosorbent assays
(ELISAs) and methods for the detection of poliovirus based on RT-PCR. While most
of these assays have been used in seroprevalence or epidemiological studies, they may
also be useful for the rapid diagnosis of poliovirus-related illness as well as for a
resolution of cases reported late after the onset of disease in the AFP surveillance
system. Therefore, this study re-examines specimens that have been collected from
patients and their contacts during a poliovirus serotype 3 outbreak in The Netherlands
in 1992/1993 [7,23,27].
Stool samples, sera, cerebrospinal fluids (CSF) and/or throat swabs were examined
from most of the 71 patients from this outbreak. In addition, stool specimens and sera
from 86 family members or close contacts of the poliomyelitis patients were
examined for poliovirus excretion and poliovirus-specific antibodies. This article
describes the application of this broader panel of diagnostic assays in order to
determine whether these tests may provide an added value for the surveillance of AFP
as a crucial step in the poliomyelitis eradication program.
Material and methods
Patients and clinical samples
Seventy-one patients were notified during the outbreak of type 3 poliomyelitis in The
Netherlands in 1992/1993 [23]. Clinical samples from 69 poliomyelitis patients were
available for analysis in the laboratory. One or more serum samples were collected
from 69 cases (97.2%), one or more stool samples were available from 58 patients
(81.7%), a CSF sample was obtained from 44 poliomyelitis cases (62.0%) and throat-
swabs were collected from 25 patients (35.2%).
Contacts of poliomyelitis patients
Stool and serum samples were obtained from 86 contacts of 25 poliomyelitis patients.
These specimens were examined for the presence of poliovirus in the stool samples as
well as for the presence of poliovirus-specific IgM and IgA antibodies in the serum
samples. Poliovirus-Binding Inhibition assays were performed to determine levels of
poliovirus type 3-specific binding antibodies [16].
Acute Flaccid Paralysis (AFP) surveillance
Recent AFP surveillance data from The Netherlands were used to calculate the added
value of the new diagnostic methods in the present AFP surveillance. Surveillance of
AFP among children younger than 15 years of age in The Netherlands started in 1992.
The measured incidence of non-polio AFP was between 0.39 to 0.87 per 100,000
children [8,24]. This was lower than the required non-polio AFP incidence of
1:100,000, indicating inadequate surveillance [8,24]. The median reporting time of
AFP cases in The Netherlands was 91 days [8]. None of the non-polio AFP cases met
the required stool sampling criterion of two samples taken 24-48 hours apart within
the first 14 days after onset of paralysis. Virus isolation was carried out in only a low
percentage (31%) of the AFP cases [8].
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Isolation of poliovirus from stool and throat swabs
Virus isolation and typing was carried out on HEp-2C and RD cells as recommended
by the WHO [29]. Poliovirus strains were differentiated as wild- or vaccine-derived
strains in an enzyme immuno assay using intra-typic cross-absorbed rabbit antibodies
[28]. The wild-type character of all of these isolates was confirmed by RNA
sequencing [19].
Poliovirus serotype-specific IgM and IgA ELISAs
The ELISAs for poliovirus serotype-specific IgM or IgA antibodies in serum from
patients and contacts were performed as described [15,20]. Poliovirus-specific IgM
was also determined in patients’ CSF [20]. Inactivated poliovirus was used as the
antigen in both assays. A positive and a negative control serum sample were included
in each assay.
Reverse Transcriptase (RT)-PCR for the detection of poliovirus in CSF
A generic enterovirus-specific RT-PCR was used to examine CSF for the presence of
polioviruses as described [26]. Viral RNA was purified from the CSF samples by
binding to silica particles in the presence of GuSCN [5].
Poliovirus-Binding Inhibition assay (PoBI)
A Poliovirus-Binding Inhibition assay was used to determine the poliovirus-specific
antibody titers as an indicator of neutralising antibodies. The PoBI assay was
performed as described [16]. The reciprocal of the first serum dilution that was
positive in the inhibition test was taken as the titer of the test sample.
Results
Virus isolation from poliomyelitis patients
Stool samples from 58 poliomyelitis patients were examined for the presence of
serotype 3 poliovirus at different times after the onset of paralysis. Stool samples
provided during the first two weeks after the onset of paralysis were most frequently
positive (89.6%) [Figure 1, Table 1]. The virus isolation rate dropped sharply to
approximately 20% in samples provided between three to ten weeks after the onset of
paralysis. No virus was isolated from any of the stool samples collected more than ten
weeks after the onset of disease [Figure 1, Table 1]. The first stool sample examined
was poliovirus serotype 3 positive in 50 of 54 polio patients (84.7%); the
accumulating positivity rate increased to 93.2% and 94.8% after examination of a
second and third specimen respectively. Throat swabs were collected during the first
two weeks after the onset of paralysis only (n=25). Virus was isolated from the throat
of 32% of the patients during this period [Figure 1, Table 1].




































































Figure 1. Positivity rates of virus isolation from stool, and of serum IgM and IgA antibodies to
poliovirus type 3 in poliomyelitis patients. Results are from consecutive serum samples
collected during the 1992/1993 outbreak in The Netherlands.








Stool 89.6 18.6 2.0
Throat 31.0 nd nd
Serology
IgM 89.5 93.9 33.3
IgA 60.7 87.1 56.7
CSF
IgM 63.6 nd nd
RT-PCR 0.0 nd nd
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Detection of poliovirus-specific IgM in poliomyelitis patients
Serotype 3-specific IgM was detectable in all serum samples from patients obtained
between three to six weeks after the onset of paralysis (n=24); a high percentage was
also positive before this period (89.5%) [Figure 1, Table 1]. Twenty percent of the
patients had low but detectable levels of virus-specific IgM three months after the
onset of paralysis.
Detection of poliovirus-specific IgA in the serum of poliomyelitis patients
Sera from 49 patients were available for the determination of poliovirus-specific IgA.
The kinetics of the IgA response in patients have been reported elsewhere [15] and
show that the IgA peak is maximal between three to eight weeks after the onset of
paralysis. Five months after the onset of paralysis, 33 (60%) of the patients still had
detectable type 3 specific IgA in their circulation [Figure 1, Table 1].
Examination of the CSF of poliomyelitis patients
A CSF sample collected during the first two weeks after the onset of paralysis was
available from 44 patients. Poliovirus type 3-specific IgM was present in 28 (63.6%)
of these CSF samples [Figure 1, Table 1]. All matching serum samples were also
positive for serotype 3-specific IgM. Sera from fourteen patients (31.8%) without IgM
in their CSF was positive for serotype 3-specific IgM.
Twenty-one CSF samples from poliomyelitis patients were examined by RT-PCR for
the presence of poliovirus RNA [Figure 1, Table 1]. Viral RNA was not detected in
any of these samples, whereas the same extracts yielded positive RT-PCR signals
after spiking with poliovirus.
Comparison of IgM, IgA and virus culture in contacts
A comparison of assays was possible for 86 contacts of poliomyelitis patients with a
complete diagnostic data set (virus isolation, IgM, IgA and PoBI). A total of 68 stool
samples were positive for the epidemic wild-type serotype 3 strain in culture (79%).
Fifty-nine (68.6%) and 46 (53.5%) contacts were positive for serotype 3-specific IgM
and IgA respectively. Eighty-five (67.5%) contacts were positive in the IgM-ELISA
and secreted poliovirus. Only ten (11.6%) contacts were excreting poliovirus in the
absence of an IgM response. Seventy-seven (89.5%) contacts had PoBI titers to
serotype 3.
The prevalence of serotype 3-specific IgM antibodies was high (86.1%) in the young
age groups (three to ten years) and declined with age [Figure 2]. The prevalence of
serotype 1- and 2-specific IgM was below 10% in all age groups. Virus excretion in
the stool was high (96.7%) within the age group ranging from three to 15 years, and
followed the same decreasing pattern with age as did the IgM seroprevalence for
serotype 3 [Figure 2C]. In contrast, poliovirus-specific IgA followed the same
patterns as the poliovirus-specific antibodies for all three serotypes [Figures 2A and
2C]. The presence of serotype 1-specific IgA, serotype 2-specific IgA and poliovirus-
binding antibodies (PoBI) increased with age and was highest in the oldest (31-80
years) age group (46.2-53.8%) [Figures 2A and 2B].
























































































































Figure 2. Prevalence of IgM, IgA and neutralizing antibodies to poliovirus type 1 [Fig 2A], type






Calculation of the theoretical benefit of the application of IgM and IgA ELISAs
for AFP surveillance in The Netherlands
Virus isolation was attempted during the first to the seventh week after the onset of
paralysis in 31% of all AFP cases reported in The Netherlands in 1995 and 1996. This
virus isolation was carried out within the recommended time period of two weeks
after the onset of disease in only 51% of these cases. The sensitivity of virus isolation
is 89.6% during this time period [Figure 1], which theoretically leads to 45.8%
correctly diagnosed AFP cases in the virologically investigated group [Figure 3A].
Stool samples from 49% of these cases were examined between three to seven weeks
after the onset of paralysis. The chance of successful isolation during this period is
18.6%, leading to a calculated percentage of correct poliovirus diagnoses in the
virologically-examined AFP patients of only 9.1% [Figure 3A]. Theoretically then,
the overall virological investigation of these AFP cases could only yield a correct
diagnosis in 54.9% of the virologically examined cases, or 17% of all reported AFP
cases.
A similar calculation was performed for the IgM ELISA [Figure 3B]. Only 15% of
the reported AFP cases were serologically examined by IgM ELISA. In the first two
weeks after the onset of paralysis, IgM-expected positivity rates were almost identical
to the rates of virus isolation from the stool (89.5%). Expected rates remained high
(93.9%) three to seven weeks later, leading to an additional 46.0% of theoretically
correctly diagnosed cases. The overall percentage of theoretically correctly diagnosed
AFP cases with the IgM ELISA was 92.0%.
Discussion
Historically, the diagnosis of poliomyelitis has relied on poliovirus isolation. Virus
isolation is still the diagnostic method of choice and was, until recently, the only
method that could reliably distinguish between wild or vaccine-virus infection.
However, several new diagnostic methods have been developed in recent years that
have not been previously evaluated under field conditions due to the lack of
poliomyelitis cases. An epidemic of serotype 3 poliovirus in The Netherlands in
1992/1993 provided the opportunity to examine the potential of a number of these
new methods [7,23,27].
Serotype 3 poliovirus from the outbreak was isolated most frequently from the stool
of poliomyelitis patients at one to two weeks after the onset of paralysis (89.6%) but
positivity rates dropped sharply thereafter to a level of less than 20%. As has been
previously described, 63% to 93% of serotype 1 stool samples test positive during the
first two weeks after the onset of disease [2]. During the third and fourth weeks after
onset, isolation frequencies for serotype 1 generally decline to a range of 35% to 75%.
Specimen positivity is usually below 50% after four weeks [2]. There is limited data
on the duration of excretion of wild strains of poliovirus types 2 and 3 [2]. However,
our study shows that poliovirus type 3 excretion seems to be about two weeks shorter
than that of serotype 1 [2].
In this study, poliovirus was isolated from the throat in only 32% of patients during
the first two weeks after the onset of disease. Because poliovirus is excreted from the
intestine for several weeks after infection, it is most frequently isolated from the stool
samples. These stool samples are, therefore, the most suitable materials for isolation
of poliovirus, confirming WHO criteria [29].
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Figure 3. Calculations of the number of correct exclusions of poliomyelitis cases by A] virus
isolation and B] IgM-ELISA.
The poliovirus-specific IgM ELISA does not discriminate between vaccine and wild-
type poliovirus-induced antibodies. However, our data show that in addition to virus
isolation from the stool, the detection of poliovirus serotype-specific IgM in AFP
patients may facilitate the laboratory diagnosis of poliomyelitis and may help to
exclude poliovirus as the causative agent. The detection of poliovirus-specific IgM
has the additional value of indicating proof of a recent infection with poliovirus even
in the absence of virus isolation. Seven cases (10%) of poliomyelitis were diagnosed
solely on the basis of IgM serology during the 1992/1993 outbreak in The
Netherlands. Virus-specific IgM in poliomyelitis patients could be detected for at least
six weeks longer than virus could be isolated from the stool [Figure 1]. An additional
advantage of the IgM-ELISA lies in the fact that it provides a result within 24 hours
compared to the five to seven days required for routine virus isolation and typing.
Poliovirus serotype 1- and 2-specific IgM antibodies were detected in a small number
(<10%) of patient contacts. The presence of these IgM antibodies is probably due to

































The percentage of samples with serotype 3-specific IgM positive results was
remarkably lower in CSF (63.0%) than in serum samples (89.5%). In addition, all
patients with serotype 3-specific IgM-positive CSF had virus-specific IgM in their
serum. Similar results were described by Roivainen et al [25] who reported that 58%
of the patients in their study had detectable poliovirus-specific IgM in their CSF,
while 94% tested positive for poliovirus-IgM in serum. These results indicate that
there is no additional diagnostic benefit of poliovirus-specific IgM detection in CSF.
Poliovirus RNA could not be detected with an enterovirus-specific RT-PCR in the
CSF samples of poliomyelitis patients. This is in contrast to results obtained in the
diagnosis of infections with other enteroviruses, where infection can easily be
confirmed in CSF by PCR and/or virus culture [1,6,9,18]. In conclusion, laboratory
examination of CSF either by PCR or by IgM assay is not recommended for the
laboratory confirmation of poliomyelitis, although it may be useful for the
determination of other causes of paralytic disease.
Not much is known about how polioviruses are able to cross the blood brain barrier.
Data from transgenic mouse experiments shows that polioviruses permeate through
the blood brain barrier at a high rate, independently of the poliovirus receptor [31]. It
has been proposed that poliovirus-infected monocytes that cross the blood brain
barrier into the CNS are a possible route [12,17].
As for IgM, the detection of serotype 3-specific IgA antibodies was much more
sensitive than was virus isolation from the stool for diagnosis of poliovirus infection
between two to eight weeks after the onset of illness. However, the presence of IgA to
serotype 3 might also reflect past rather than recent infection because of the
persistence of the IgA isotype in the bloodstream after infection. For this reason, the
detection of poliovirus-specific IgA is less suitable for the detection of recent
poliovirus infection.
Previously, we described that the seroprevalence of poliovirus-specific IgA was
significantly lower in young IPV-vaccinated children compared to older IPV-
vaccinated individuals and to a group of naturally exposed persons. These results
could not be explained by the IPV vaccination schedule [15] and we therefore
hypothesised that the presence of circulating IgA in the population of The Netherlands
reflects past contact with live poliovirus (wild poliovirus or OPV vaccine strains)
rather than vaccination with IPV [15]. In the present study, we found a similar age-
related increase of poliovirus-specific antibodies to serotype 1 and 2 in these contacts
(determined with the PoBI) and poliovirus-specific IgA for serotype 1 and 2 in up to
53.8% of the contacts of poliomyelitis patients. Because these contacts belong to the
same community that rejects vaccination, these IgA levels probably indicate natural
exposure at a level similar to that observed in the general Dutch population. The
serotype 1 outbreak that occurred within the risk group in 1978 [4,13] can explain the
presence of antibodies to serotype 1 poliovirus. During this outbreak, serotype 1
circulated extensively, while at the same time, monovalent OPV type 1 was offered to
the community at risk [4].
One of the strategies used for the eradication of poliomyelitis is the surveillance of
patients with AFP. Performance criteria have been established to provide compelling
evidence for high quality AFP surveillance. Adequate AFP case investigation includes
the collection and laboratory investigation of two stool samples within 14 days after
the onset of paralysis [30]. There is a long delay in reporting AFP cases in The
Netherlands, which makes AFP surveillance in its present form insufficient as a tool
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for the documentation of the absence of poliovirus. Only 31% of the reported AFP
cases were virologically examined in The Netherlands [8], implying that poliovirus
infection could not be excluded with certainty in 69% of these cases [24]. In addition,
a further 12.4% of the virologically examined group could not be successfully
diagnosed due to late sampling. When serum samples are available, the IgM ELISA
may be helpful in resolving those cases of AFP that cannot be definitely classified as
poliomyelitis retrospectively.
Reliable diagnostic virology depends upon the timely and correct collection of clinical
specimens. Although stool samples should be collected as soon as possible, preferably
within the first two weeks after the onset of paralysis, this does not always occur.
Therefore, other methods such as the poliovirus serotype-specific IgM ELISA could
serve as an important complementary tool for the diagnosis or exclusion of
poliomyelitis in AFP patients, especially in the post-eradication era. Although the
poliovirus-specific IgM assay cannot replace virus isolation from a clinical case, the
method has proved to be very helpful for the rapid diagnosis of poliomyelitis and for
the exclusion of poliovirus infection as the cause of AFP.
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Both the (enhanced) inactivated poliovirus vaccine (e)IPV and the oral poliovirus
vaccine (OPV) are capable of inducing high levels of circulating neutralising
antibodies and both provide excellent protection against poliovirus-induced disease.
The introduction of these vaccines has resulted in the elimination of poliomyelitis
from most parts of the world and represents one of the greatest achievements of
medical science. However, global eradication of poliovirus can only be considered
complete when: a) no more cases of poliomyelitis caused by wild-type poliovirus
occur and b) poliovirus no longer circulates in (vaccinated or non-vaccinated) humans
and is no longer present in the environment [82].
It is essential that vaccination be continued even after paralytic disease has been
eliminated so that the complete absence of wild-type poliovirus in the population and
in the environment can be achieved. Mucosal immunity is considered to be of great
importance for the interruption of poliovirus transmission and consequently for a
reduction of the spread of poliovirus within the population. The experiments
described in this thesis have been conducted in order to study the contribution of IPV
vaccination to immunity from and protection against poliovirus infection. Our data
may shed new light in the use of IPV in the course of the eradication programme.
The mechanism of induction of poliovirus-specific IgA after vaccination with
IPV
The mechanism by which IPV (booster) vaccination can induce poliovirus-specific
IgA after previous mucosal priming is unknown. IPV is applied intramuscularly in a
clear peripheral tissue site. Lymph nodes are strategically located in the body to drain
specific tissues and to process antigens deposited in these tissues, and antigens are
transported to lymph nodes by antigen presenting cells through the afferent lymphatic
system [59]. These antigens probably stay localised due to the fact that IPV does not
replicate in the host and, as a consequence, the generation of a specific immune
response will be initiated within the organised lymphoid structures of the draining
lymph nodes [59].
Expanded populations of antigen-specific effector lymphocytes and memory
lymphocytes leave the lymph node through the efferent lymphatics to find their way
into the peripheral blood circulation via the thoratic duct system. In our experiments,
poliovirus-specific IgG- and IgA-producing cells were detected at 7 days after an IPV
booster vaccination [Chapter 5]. Lymphocytes migrate from the blood into tissues and
lymph nodes via specialised capillary vessels. This occurs through the interaction of
the cellular homing receptors that are expressed on the activated lymphocytes and
their ligands on the vessel walls [9]. The final combination of homing receptors on the
cells’ surface is likely to account for the regional preference of the activated cells.
Lymphocytes activated in peripheral or mucosal lymphoid compartments are thought
to migrate preferentially back to peripheral and mucosal tissue sites respectively
[9,68]. However, IPV vaccination induced a strong memory IgA response at
peripheral and mucosal levels under the condition of previous mucosal priming
[Chapter 5]. These results indicate that memory B cells spread to both the peripheral
and mucosal compartments after OPV vaccination or natural infection.
We have described how at least part of the poliovirus-specific IgA producing cells re-
activated by IPV expressed both L-selectin (indicating homing to peripheral lymph
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nodes) and the mucosal homing receptor a4b7 integrin on their surfaces (Chapter 5).
This indicates homing to both the mucosal and peripheral compartments. These
primed B cells may encounter IPV-derived antigen-specific peptides in the peripheral
lymph nodes, resulting in the production of IgA following IPV booster in mucosally
primed persons.
There is no information at present regarding the induction and homing potentials of
memory T cells after vaccination in humans. Premier (et al.) used in vitro
proliferation assays to conduct an interesting study on the distribution of ovalbumin-
specific memory T cells to the different peripheral and mucosal lymph nodes in sheep
after previous peripheral and mucosal immunisation [59]. Their results suggested that
antigen-specific proliferative T cells preferentially migrate to peripheral lymph nodes
(independent of their site of induction) where they may modulate the immune
response following repeated antigen exposure [59].
A possible role for bone marrow in memory IgA response after IPV vaccination
The majority of Ig-secreting cells in mammals are localised in bone marrow [2,28].
Furthermore, it is well established that after systemic immunization (such as IPV),
bone marrow is the major site of antibody production during a secondary immune
response [2,3]. The induction of this immune response actually occurs in lymphoid
tissues. Stimulated cells then migrate from the secondary lymphoid organs to the bone
marrow [1,38]. Bone marrow has also been described as an important site for the
production of IgG and IgA antigen-specific antibodies after mucosal immunisation
(OPV) [5,66]. The induced poliovirus-specific IgA antibody producing cells originate
as precursors from the Peyer’s patches. After OPV vaccination, they migrate through
the lymphatic ducts that drain the gut-associated lymphoid tissue (GALT) and the
mesenteric lymph node. They then enter the blood circulation via the intestinal and
thoratic duct lymph. These activated lymphocytes leave the circulation in the lamina
propria, other mucosal sites and the bone marrow, where they reside as IgA producing
plasma cells [5,10,17,33].
The importance of bone marrow as an effector site of the immune response induced in
the GALT is suggested by the fact that IgG- and IgA-secreting cells are deficient in
the bone marrow of germ-free mice [4]. Antigenic peptides may also reach the bone
marrow after renewed antigenic stimulation (by IPV), resulting in a strong recall
response of the resident blasts. In previously OPV-vaccinated persons, this will
include B cells differentiated to produce poliovirus-specific IgA. The exact role of
bone marrow in poliovirus immunity induced by IPV and OPV vaccination remains to
be investigated.
The importance of T cells in poliovirus immunity
The exact importance of T cell mediated immunity to poliovirus and its role in viral
clearance and protection from re-infection is not known. Neutralising antibodies are
thought to be important for clearing poliovirus infections and for protecting against
paralytic disease, because children with agammaglobulinemia often develop persistent
poliovirus infections [80]. However, it is impossible to cure these patients or clear the
poliovirus from the CNS even with infusion of high titered antibodies into the
cerebrospinal fluid [45,61]. In addition, poliovirus persistence has been described in
people with pure T cell deficiencies but with normal immunoglobulin levels and
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normal antibody responses [29]. Thus, T cells and/or other cellular immune
mechanisms play at least a partial role in the clearance of poliovirus.
The immune response to picornaviruses, including the development of a neutralising
antibody response, is generally T cell dependent as shown in experimental studies
with foot-and-mouth disease virus [14,15]. T cell-mediated cytotoxicity has been
described as crucial for the resolution of infections with non-cytopathic viruses,
whereas infections with cytopathic viruses (like poliovirus) are mainly cleared by
soluble mediators such as neutralising antibodies and interferons that stimulate the
aspecific cellular immunity [37].
T cells recognise linear peptide fragments of virus-encoded proteins associated with
major histocompatibility complex class I (HLA-A, -B and -C determinants [CD8+
cells] or MHC class II (HLA-DR,-DP, and –DQ [CD4+ cells]) [26]. CD4+ T helper
(Th) cells have been divided into at least two different subsets (Th1 and Th2) based
on the cytokines that they produce upon antigen stimulation [47]. Th1 cells secrete
interleukin 2 (Il-2), interferon gamma (IFN-g) and tumour necrosis factor beta (TNF-
b). These cells stimulate cell-mediated cytotoxicity, whereas Th2 lymphocytes
produce Il-4, Il-5 and Il-10 and help B cells to produce neutralising antibodies [78].
Although these functionally distinct T cells were originally described in the mouse,
human T cell clones possess similar but not identical restricted cytokine profiles [27].
Because humoral immunity appears to be of primary importance in the protection
against poliovirus disease, one might expect a predominance of Th2 cells that are best
adapted to helping B cells produce antibodies [11,14,15]. However, complement
depletion and monoclonal antibody inhibition studies with humans have shown that
the effector population after OPV vaccination was of the Th1 subclass [65]. This and
other examples have made it clear that the Th1/Th2 dichotomy may not be as clear in
humans as it is in mice [27].
Cytotoxic CD8+ T cells specific for picornaviruses have been described [32,73], and
CD8+ MHC class I restricted T cells have been largely associated with the cytotoxic
T-lymphocytes (CTL) function [84]. Recent evidence from cloned murine T cells
suggests that CD4 positive Th1 cells are also involved in direct cell-mediated
immunity, including the lysis of virally infected target cells [13,47,56].
Results from (transgenic) mouse experiments are consistent with results obtained
using human participants [43,44,78,79]. CD4+ T cells mediated delayed type
hypersensitivity (DTH) and T cell proliferation responses to poliovirus in mice, after
systemic vaccination with UV-inactivated poliovirus [78,79]. These CD4+ cells
included Th1 cells mediating delayed type hypersensitivity (DTH) responses and
cytotoxicity as well as Th2 cells that stimulate B cells to produce neutralising
antibodies [78]. Other studies in mice have identified poliovirus-specific T cell
epitopes recognised by both MHC class I-restricted cytotoxic T cells and class-II
restricted T helper cells [39,40,41,44].
No virus replication takes place in the cells of vaccine recipients after vaccination.
After intramuscular injection, therefore, poliovirus antigens will be presented mainly
through specialised antigen presenting cells such as macrophages and dendritic cells
[67]. Although data on cellular immunity following IPV vaccination are lacking, it is
likely that the presentation of antigen peptides will occur by the MHC class-II
molecules to predominantly CD4+ T cells [26]. CD4+ T cells are important for the B
cells’ production of virus-specific antibodies, and this may explain the high induction
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of neutralising antibodies and high seroconversion rates after only one dose of IPV
(>90%) compared to OPV vaccination (40%) [7,57].
OPV viruses are able to replicate within the host. Therefore, viral antigen will also be
presented to the immune system through the MHC-I molecules present on infected
cells, which will consequently give rise to the stimulation of cytotoxic CD8+ T cells
[67]. The stimulation of CD8+ T cells may in turn result in the clearance of poliovirus
infections. CD8+ T cell responses are also detected after OPV vaccination, probably
following contact between antibody presenting cells and debris from poliovirus lysed
cells and intact poliovirus particles [65].
T cell responses after poliovirus infection and vaccination in humans have not been
studied extensively and their capacity to evoke memory responses is largely unknown.
In general, T cells play an important role in protection against re-infection by
inducing rapid memory responses through the activation of memory B cells [72].
UytdeHaag (et al.) showed that the production of neutralising antibodies to poliovirus
in vitro could be generated by the re-stimulation of cultured human lymphocytes with
antigen, but only in the presence of Th2 cells [72].
Other unanswered questions pertaining to poliovirus-induced immunity relate to the
possible role of other cellular factors such as natural killer (NK) cells and the genetic
constitution of the host. It has been demonstrated that NK cells provide protection
against enterovirus infection by limiting virus replication [25]. Most NK cells have Fc
receptors and may induce antibody-dependent cell-mediated cytotoxicity [30].
However, the role that NK cells play during poliovirus infection is not known.
Studies on the influence of MHC restriction (HLA) on susceptibility to paralytic
poliomyelitis have yielded conflicting results [19,58,83]. More recently, resistance to
paralytic poliomyelitis has been suggested to be HLA-related [76]. Thus, while
susceptibility to paralytic poliomyelitis in humans may be genetically influenced, it is
unclear at this time what these influencing factors are [79].
Further research is needed to understand the precise role of cellular immunity in the
protection against re-infection with polioviruses.
Circulation of poliovirus during the 1992-1993 epidemic in The Netherlands
The use of IPV vaccination combined with the existence of communities refusing
vaccination on religious grounds makes The Netherlands unique. Epidemics within
these groups have revealed poliovirus circulation within The Netherlands that would
otherwise have gone undetected [8,54]. It was uncertain whether poliovirus
circulation would be restricted to the unvaccinated risk groups during the 1992-1993
epidemic, and studies were conducted during this outbreak [16,74] in which stool and
sewage samples were examined in and outside the risk area to determine the spread of
poliovirus circulation. Although over 3000 stool samples were investigated, virus was
isolated only from 8 persons (all in the risk area).
The lack of poliovirus circulation outside the risk groups supported the hypothesis of
the existence of sufficient herd immunity in the IPV-vaccinated population. However,
it is known that the chance of virus isolation in susceptible non-vaccinated subjects is
(in most cases) limited to the first two to three weeks after infection [Chapter 6]. A
cross-sectional study conducted during an epidemic can therefore be described as a
search for the proverbial ‘needle in a haystack’.
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The widespread OPV vaccination during the outbreak could have had a negative
effect on the sensitivity of wild-type isolation. Interference between Sabin and wild-
type strains in in vitro cultures has been demonstrated [75].
Poliovirus was also isolated from sewage samples during the epidemic. None of the
samples collected outside the risk area and only 4.5% of the samples within the risk
area tested positive for the endemic strain, illustrating the low sensitivity of sewage
testing for wild-type poliovirus [74]. Further, OPV circulation may have interfered
with the successful isolation of wild-type virus, as OPV was used to control the
epidemic [75]. In conclusion, both the population and the sewage surveillance studies
indicate that it is difficult to detect circulation within the population and in the
environment even under ‘ideal’ (epidemic) conditions with proven widespread
circulation of wild-type poliovirus [55]. The low negative predictive value of virus
isolation under these circumstances implies that populations can not be declared free
from poliovirus circulation based on these methods alone.
Implications of the lack of mucosal IgA induction by IPV vaccination for the
transmission of poliovirus
Mucosal immunity is one of the most important factors influencing protection against
re-infection and is essential for the reduction of poliovirus circulation in the
population [24,51,52]. The induction of mucosal IgA may therefore be of particular
importance for the poliomyelitis eradication program. We have shown that IPV-
vaccination alone is insufficient to induce mucosal IgA [Chapter 5]. This finding is a
clear indication of the remaining susceptibility of IPV recipients to poliovirus
infection, even though they are protected against disease.
One has to keep in mind that there is a clear difference between protection against
disease and protection against infection. Complete protection against disease is
achieved in all fully IPV- and OPV-vaccinated persons. However, it is sometimes
mistakenly believed that the absence of clinical cases induced by poliovirus is
evidence for a break in the chain of transmission or even the (complete) absence of
poliovirus circulation.
It has been shown that both IPV and OPV recipients can be re-infected with
polioviruses, thereby contributing to the chain of transmission [31,54,70]. Outbreaks
of poliomyelitis in Finland [31], The Netherlands [54] and Oman [70] have
demonstrated that wild-type poliovirus can replicate in vaccine recipients (IPV or
OPV) without clinical disease, and that it can then spread to other (susceptible)
persons.
Possible silent circulation of poliovirus in The Netherlands?
Poliovirus infection can spread unnoticed within a population because it may take
several hundred infections among non-vaccinated or inadequately vaccinated subjects
to produce one paralytic case. This ratio varies according to serotype and is highest
for serotype 3 (estimated at between 4000:1 and 500:1 [20,46,63]). The lowest ratio is
detected for serotype 1 (between 60:1 to 175:1 [46]) and intermediate values are




If silent circulation does occur, it must come to a complete stop before vaccination
can end. Unfortunately, poliovirus circulation within The Netherlands is not being
studied extensively at present. However, all poliovirus strains isolated in clinical
virology laboratories in The Netherlands are sent to the RIVM for further analysis
[62]. Wild-type polioviruses were isolated from three imported cases of poliomyelitis
during the time period between the 1978 and 1992/1993 outbreaks [62]. Between
1979 and 1989, wild-type strains were isolated on 44 occasions from 5868 stool
samples, all from adopted children who had recently entered the country (11 x
serotype 1, 13 x serotype 2 and 20 x serotype 3) [62]. Twenty-one wild-type strains
(15 x serotype 1 and 6 x serotype 3) were reported between 1979 and 1990, all
isolated from persons with a history of international travel [62]. These results indicate
a continued importation of wild-type polioviruses into the general population of The
Netherlands and the continued threat of exposure to wild-type poliovirus into the
(non-) vaccinated community, but provide no evidence for continued circulation in
The Netherlands.
However, indications for silent circulation in The Netherlands do exist. For example,
wild-type poliovirus strains were detected 13 times in 58 water samples from the
Rhine and Meuse rivers during the period between 1979 to 1989 (11 x serotype 1, 1 x
serotype 2 and 1 x serotype 3) [62]. Interestingly, researchers repeatedly isolated of
viruses identical or closely related to the epidemic serotype 1 strain from 1978 (<3%
sequence divergence) up to 5 years after the epidemic [48]. These viruses were found
both in clinical and environmental specimens until 1983 [48]. This continued isolation
is more likely explained by continued circulation in the population rather than a
repeated introduction of exactly the same wild-type poliovirus strain into The
Netherlands.
Another indication that silent circulation may exist comes from a serosurvey among
non-vaccinated schoolchildren born between 1962 and 1968 [62]. These children
developed antibodies to the serotype 1 strain during the 1978 outbreak [48]. The
children also demonstrated antibodies to serotype 3, indicating that they had already
been exposed to this serotype [62]. This finding led to the conclusion that serotype 3
must have circulated between 1968 and 1978 [62].
As in the 1978 type 1 poliovirus epidemic in The Netherlands, the type 3 epidemic
that occurred in Finland in 1984 seemed to have had its source in the Mediterranean
region [31,48]. Genetically similar viruses (<4% sequence divergence) were isolated
on three separate occasions in The Netherlands between 1980 and 1982. Therefore,
the theory that the Finland epidemic strain might have originated in The Netherlands
cannot be excluded.
Finally, mucosal contact with live poliovirus (wild-type or OPV) is suggested by our
own data: we demonstrated that IPV alone is incapable of inducing IgA and yet we
found a high seroprevalence (12.1 to 27.3%) of IgA in healthy blood donors [Chapter
4]. The findings described above do not prove the local circulation of wild-type
poliovirus, but can not solely be explained by virus importation. More sensitive
surveillance tools must be developed to ensure that poliovirus transmission is halted.
When can we be sure that poliovirus has been eradicated?
Eichner and Dietz [22] calculated that a case-free period of over three years must be
observed before one can be 95% certain that wild-type poliovirus is no longer present
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in the population. These calculations were based on the assumptions that 80% of the
population were immunised, that IPV recipients were partly protected from infection
(with a simulated 50% reduction in virus excretion) and that previously infected
persons were fully protected against re-infection. The calculations did not take the
importation of virus strains from other countries into consideration [22].
Vaccination acceptance in The Netherlands is high (>97%) [77]. Under these
circumstances, the probability of polio-like symptoms in the general population after
re-infection is very low [16,62]. The presence of poliovirus-specific IgA at mucosal
sites is important for the reduction of viral excretion [51-53]. Our finding that no
poliovirus-specific IgA is induced at mucosal sites after IPV vaccination [Chapter 5]
makes Eichner and Dietz’s assumption that IPV recipients were partially protected
less likely [22]. In addition, several cases of wild-type poliovirus importation into The
Netherlands have been reported [48,62]. Together, these findings challenge the idea
that the virus will be eliminated after a three-year polio-free period in IPV-vaccinated
populations. Studies investigating resistance to an OPV challenge in IPV-vaccinated
persons with and without poliovirus-specific mucosal IgA are currently underway.
Vaccination with OPV results in the release of a wide variety of live mutant viruses in
the stool [12], some of which are highly virulent (even in countries declared to be
‘polio free’) [60]. A stricter definition of eradication should include the elimination of
all polioviruses (including OPV) from the population and the environment. This goal
cannot be accomplished using the current protocol of OPV vaccination, and will
require the exclusive use of IPV in the final stages of poliovirus eradication combined
with intensive surveillance for wild-type poliovirus.
Our data indicate that IPV can serve as a strong inducer of mucosal immunity after
previous mucosal priming with live viruses [Chapter 5]. This finding indicates that a
combination schedule of OPV and IPV vaccination could serve as a powerful tool in
the final stages of the eradication program. However, this may also lead to
complicated vaccination schedules. Another option is to stop ‘cold-turkey’, meaning a
complete cessation of polio vaccination upon reaching a certain polio-free period after
the last clinical case of poliomyelitis. However, this might be a risky proposition in
the absence of sensitive tools to check for wild-type poliovirus circulation in the
vaccinated population.
The detection of poliovirus-specific IgA as a marker for previous mucosal
priming and poliovirus circulation
Poliovirus-specific IgA is readily detected in the serum after wild-type infection
[51,52]. No mucosal poliovirus-specific IgA was produced after an IPV booster
vaccination of IPV-vaccinated adult volunteers, and serum IgA was only detected in
some volunteers at a low level [Chapter 5]. Because these volunteers had been
vaccinated years ago, a recent study involving a group of nine year-old children from
The Netherlands was conducted to search for the presence of poliovirus-specific IgA
in serum four months after a sixth IPV vaccination [62]. None of the children in this
group had serotype 1- or 3-specific IgA and only 5.8% were found positive at low
levels for serotype 2-specific IgA [Herremans et al., unpublished results]. This
confirmed the results from the study described in Chapter 5. The absence of
poliovirus-specific IgA after IPV vaccination may enable its use as a marker for the
detection of poliovirus circulation within an IPV vaccinated population. Both saliva
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and serum samples could be used in a large scale screening of the population for the
presence of poliovirus-specific IgA.
Although not much is known about the persistence of poliovirus-specific IgA after
exposure to live polioviruses, 36% of a group of poliomyelitis patients were still
positive five months post-infection [Chapter 4]. Further investigations examining the
possibilities and sensitivity of applying the IgA ELISA for this purpose are currently
underway.
The detection of antibodies to the non-structural proteins of poliovirus as a
marker for circulation
Another method that may be used to discriminate between antibodies induced by IPV
vaccination and those induced through mucosal contact with a replicating poliovirus
(wild-type or OPV strain) is the detection of antibodies against the non-structural
proteins of poliovirus. Poliovirus has seven different non-structural proteins (2A to 2C
and 3A to 3D). These proteins are expressed during virus replication in the host and
are subsequently presented to the immune system. No virus replication occurs after
vaccination with inactivated poliovirus, and therefore no induction of antibodies
specific for the non-structural proteins will occur.
While this test cannot discriminate between OPV vaccination and wild-type infection,
such an assay may be very useful in IPV-vaccinated populations. The 3ABC and 3D
non-structural proteins have been successfully used in the surveillance of foot and
mouth disease [6,21]. The 3C non-structural protein has been tested with success for
another (human) picornavirus (hepatitis A) [69]. Both direct ELISA,
immunoprecipitation and immunoblotting were used to detect antibodies to viral non-
structural proteins [6,21,69]. The literature indicates that 3C (protease) has the largest
antigenic variation in non-structural proteins of picornaviruses [57]. Cross reactivity
between polioviruses and coxsackie A12 has also been described [57]. Coxsackie
A12, A24 and polioviruses belong to the same genetic group based on alignment of
the coding regions of picorna viruses. Further, other epitopes on the non-structural
proteins might be shared with other picornaviruses and might cause cross-reactions.
We will conduct future studies to develop and evaluate assays for the determination of
antibodies to recombinant non-structural proteins of poliovirus. This will assist efforts
to monitor the absence of poliovirus circulation in The Netherlands. However, there
are some reports describing the presence of non-structural proteins (2C, 3CD, 3C and
3D) in the viral capsid of (inactivated) poliovirus [49,50]. Therefore, it remains to be
seen whether infection-specific assays can be developed.
Possible side effects of poliovirus eradication
All countries will benefit from ending polio vaccination once global eradication has
been achieved. Human and financial resources will become available for other health
priorities. Despite the great benefits of polio eradication, however, some side effects
may occur. Cross-reacting T cells and neutralising antibodies between poliovirus and
other enteroviruses have been described [11,18,43,64]. Samuelson et al. [64]
demonstrated that the essential residues for the binding of cross-reactive antibodies
are well conserved within the enterovirus family. Most cross-reacting neutralising
antibodies are directed against VP1 [64], while cross-reacting T cells are thought to be
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directed mainly against VP4 [11]. In addition, cross-reacting antibodies and T cells
directed against NSPs have been found [42].
It is possible, therefore, that poliovirus vaccination also induces some level of
protection against other enterovirus infections. Enterovirus infections are very
common during infancy, and most children experience at least one enterovirus
infection during their first year of life [11,35]. Enteroviral infections have been linked
to the pathogenesis of auto-immune diseases such as chronic cardiomyopathies and
insulin-dependent diabetes mellitus [34,81]. There are some indications that cross-
reacting T cells induced by polio vaccination might have a protective effect against
the induction of insulin-dependent diabetes mellitus in young children, thought to be
related to coxsackie B virus infections [36].
Time will reveal the specific consequences that polio eradication will have on the
incidence of other enteroviral infections (most of which are now asymptomatic)
[11,35]. Further investigation is necessary to determine the effects on enterovirus
infections if polio-vaccination is stopped.
Final considerations
Despite all of the problems discussed above, we are well on our way to the world-
wide eradication of poliovirus through the use of the currently available IPV and OPV
vaccines. Before vaccination stops, however, we must ensure that all (silent)
circulation of poliovirus within vaccine recipients is terminated. Poliovirus infections
in vaccinated recipients are hard to detect, since none of these people will develop any
clinical signs. It is for this reason that the absence of clinical cases induced by
poliovirus in a vaccinated population can never serve as compelling evidence of
poliovirus eradication. More sensitive tools must be developed to ensure that
poliovirus transmission is halted in the vaccinated population.
To this end, IPV vaccination may assume an important role in the final stages of polio
eradication. It does not introduce live poliovirus into the environment, and it also
allows the development of markers other than direct poliovirus isolation in the general
population.
We were able to detect poliovirus-specific IgA in young IPV-vaccinated children,
indicating that they have never been in contact with live poliovirus. This is a clear
indication that we are on the right track towards the elimination of poliovirus from
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The aim of this thesis was defined as the study of the contribution of IPV vaccination
to the induction of a) protection against poliovirus infection and b) mucosal immunity.
We have described the development of new immunological tools for the rapid
detection of poliovirus-specific antibodies and have investigated the induction of
mucosal immunity after IPV vaccination. Our studies compared the immunity induced
by IPV vaccination to the immune responses after OPV vaccination and/or exposure
to wild-type poliovirus.
The presence of antibodies that protect individuals from poliomyelitis is usually
determined by a neutralisation assay using cell cultures. Cell culture assays, however,
are technically demanding. Disadvantages of the serum neutralisation test (NT)
include its long duration and the need for a manual screening of the test results,
making this assay labour intensive, difficult to standardise and less suitable for the
screening of large populations. Other assays able to detect poliovirus-specific
antibodies have been developed within the last decade [6,7]. However, the new assays
estimating immunity to polioviruses measure both neutralising and non-neutralising
antibodies, whereas it is the presence of neutralising antibodies that is correlated with
protection from (re)infection.
A newly developed inhibition ELISA known as the PoBI test (Chapter 2) can replace
the NT for the determination of protective levels of antibodies to polioviruses in large-
scale population studies. Correlations between the PoBI test and the NT were high:
0.89, 0.89 and 0.84 for serotypes 1, 2 and 3 respectively. The sensitivity of the
inhibition ELISA was 98.6%, 97.4% and 92.1% for serotypes 1, 2 and 3 respectively.
The specificity of the PoBI test as determined with sera from non-vaccinated persons
was also high for all three serotypes (99.0%, 95.8% and 100% for serotypes 1, 2 and 3
respectively). One of the major advantages of the PoBI test over the NT is the use of
inactivated virus as the antigen. In view of the ongoing eradication of poliovirus, the
use of live poliovirus in diagnostic assays should be discouraged and must cease
altogether in the near future. Under these circumstances, the PoBI assay is an
excellent replacement for the standard NT.
Three important antigenic sites (epitopes) involved in virus neutralisation have been
identified on polioviruses in mouse experiments [13]. It has been reported that trypsin,
present in the intestinal fluids, can cleave serotype 3 polioviruses at antigenic site 1
[14]. Trypsin cleavage of poliovirus results in drastically altered antigenic properties,
and trypsin-cleaved viruses may escape neutralisation by monoclonal antibodies to
antigenic site 1 [9].
Antibody responses to antigenic sites 1 and 3 were determined in fully IPV- or OPV-
vaccinated recipients and in individuals who had been naturally infected (Chapter 3)
in order to study the immunogenicity of these sites in humans and the effect of trypsin
exposure in vivo. Both sites were immunogenic in naturally infected humans. No
significant differences were detected in the responses to antigenic site 1 between IPV-
and OPV-recipients. However, significantly more OPV recipients (88.7%) had
detectable antibodies to antigenic site 3 (p<0.01) when compared to IPV-vaccinated
persons (63.1%).
While there are no major differences in the systemic humoral immune response
between IPV- and OPV-vaccinated persons, it is not clear whether parenteral
vaccination with IPV can lead to priming of the mucosal immune system. We
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developed and evaluated ELISAs for the detection of poliovirus serotype-specific IgA
and secretory IgA antibodies, and used these assays to examine IgA responses after
wild-type infection or vaccination (described in Chapter 4). All of the examined
poliomyelitis patients developed a humoral poliovirus-specific IgA response after
infection with wild-type poliovirus. In addition, poliovirus-specific IgA was found
more frequently in OPV-vaccinated persons than in IPV-vaccinated persons.
We observed an age-related increase in the seroprevalence of IgA in the IPV-
vaccinated population of The Netherlands. These results may be explained by the
assumption that IgA is induced by infection with live poliovirus (wild-type or OPV
strains) in the older population, and is unrelated to the IPV vaccination schedule. This
is best illustrated by the finding that children between the ages of 13 and 15, born
prior to the serotype 1 outbreak of 1978, had significantly more serotype 1-specific
IgA in their serum than serotype 2- or 3-specific IgA. We also found that parenteral
vaccination with IPV was able to boost IgA responses in 74% to 87% of a naturally
exposed population. While the presence of IgA in IPV-recipients has been previously
documented, our findings support the hypothesis that mucosal priming with live virus
is necessary to obtain an IgA response after IPV booster vaccination.
A group of fully OPV- or IPV-vaccinated recipients were given a booster vaccination
with IPV to investigate the effect of IPV vaccination on the mucosal IgA response
(described in Chapter 5). ELISA and ELISPOT-assays were used for the detection of
poliovirus-specific IgA responses. No induction of poliovirus-specific IgA was
detected in either saliva or stool samples from individuals in the IPV-vaccinated
group, and no IgA-producing cells could be detected in their blood. These findings led
to the conclusion that IPV vaccination is unable to induce a response to poliovirus at
the mucosal level, indicating the possibility of a lower level of protection against
(re)infection in IPV recipients.
However, IPV did induce high levels of circulating IgA in fully OPV-vaccinated
subjects at both the humoral and the mucosal level. When B cell populations were
separated on the basis of the expression of mucosal (a4b7 integrin) or peripheral (L-
selectin) homing receptors, a large percentage (77.3%) of the poliovirus-specific IgA-
producing cells in the previously OPV-vaccinated group expressed the a4b7 integrin.
It was concluded that IPV vaccination alone is insufficient to induce a mucosal IgA
response against poliovirus. Our results did indicate, however, that IPV vaccination
can serve as an excellent stimulator of mucosal immunity in mucosally (OPV) primed
individuals. These observations indicate that the interpretation of findings from
challenge studies using IPV recipients must take into account subjects’ possible
previous contact with live poliovirus. Subjects from endemic regions, for example,
may have had previous exposure to live poliovirus, and this may explain the reported
induction of mucosal IgA by IPV vaccination in the past [2,5,8,10,16,17,19].
Cases of poliomyelitis in which paralysis occurs are very difficult to distinguish
clinically from other cases of acute flaccid paralysis (AFP). Several new diagnostic
methods have been developed in recent years (in our laboratory and elsewhere) that
have not been evaluated under field conditions [3,4,10,11,15,18]. While the
virological investigation of stool samples is important, it is a laborious procedure [1].
The detection of poliovirus serotype specific-IgM in AFP patients facilitates the
laboratory diagnosis of poliomyelitis and helps to exclude poliovirus as the causative
agent (Chapter 6). In fact, virus-specific IgM was detected in the blood for six weeks
longer than virus was able to be isolated from stool samples. Poliovirus-specific IgA
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persisted in many patients for more than eight weeks after infection and may therefore
reflect past exposure rather than a recently acquired infection. For this reason,
poliovirus-specific IgA is less suitable for the diagnosis of recent infections.
Reports of AFP cases in The Netherlands often succumb to serious delays. As a result,
AFP surveillance (in its present form) is not an adequate tool with which to document
the absence of poliovirus. To make matters worse, only 18.6% of reported AFP cases
are virologically examined in The Netherlands (according to WHO guidelines [1,12]).
This implies that poliovirus infection can not be excluded with certainty in 69% of
these cases. The IgM ELISA will be helpful in resolving cases of AFP that cannot be
retrospectively classified as poliomyelitis and for which serum samples are available.
Despite all of the problems discussed above, we are well on our way to the world-
wide eradication of poliovirus through the use of the currently available IPV and OPV
vaccines. Before vaccination stops, however, we must ensure that all (silent)
circulation of poliovirus within vaccine recipients is terminated. Poliovirus infections
in vaccinated recipients are hard to detect, since none of these people will develop any
clinical signs. It is for this reason that the absence of clinical cases induced by
poliovirus in a vaccinated population can never serve as compelling evidence of
poliovirus eradication. More sensitive tools must be developed to ensure that
poliovirus transmission is halted in the vaccinated population.
We were able to detect poliovirus-specific IgA in young IPV-vaccinated children,
indicating that they have never been in contact with live poliovirus. This is a clear
indication that we are on the right track towards the elimination of poliovirus from
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Tijdens de laatste polioepidemie in Nederland in 1992/93, waarbij 71 slachtoffers
vielen onder principieel niet-gevaccineerden, rees de vraag of het poliovirus ook nog
bij het gevaccineerde deel van de bevolking voorkomt. Het zou kunnen zijn dat
gevaccineerden het virus bij zich kunnen hebben zonder ziek te worden. Als dat het
geval zou zijn zouden gevaccineerden kunnen bijdragen aan het besmetten van
principieel ongevaccineerden. Deze vraag is bovendien belangrijk omdat onder
leiding van de wereldgezondheids- organisatie getracht wordt het poliovirus uit de
wereld te bannen. Pas nadat men zich er van verzekerd heeft dat nergens meer
poliovirus circuleert, kan worden gestopt met vaccineren. Dan is de uitroeiing van
polio een feit. De huidige poliovirus vaccins geven een uitstekende bescherming tegen
de ziekte, dat wil zeggen tegen het ontstaan van verlammingen nadat poliovirus is
binnen gedrongen in het lichaam. Voor het uitroeiings- programma is het belangrijk
dat vaccins nog een stapje eerder hun werk doen, namelijk door te voorkomen dat
poliovirus het lichaam binnenkomt. Immers, wanneer dit het geval is, heeft het virus
geen mogenlijkheid meer om zich te handhaven. Dit is alleen het geval als er ook een
mucosale immuniteit bestaat. Dat betekent dat op de slijmvliezen antistoffen tegen
poliovirus aanwezig is die er voor zorgen dat het virus zich niet kan nestelen op de
slijmvliezen.
Het doel van dit proefschrift was het bestuderen van de bijdrage van vaccinatie met
geinactiveerd poliovaccin (IPV) bij het induceren van bescherming tegen poliovirus
infecties en het induceren van mucosale immuniteit. IPV wordt in Nederland gebruikt
in het rijks vaccinatie programma. Wij hebben nieuwe methoden ontwikkeld om op
een eenvoudige en snelle manier poliovirus-specifieke antistoffen aan te kunnen tonen
als mede ook assays om de mucosale immuniteit te kunnen bestuderen. Wij hebben
vaccinatie met IPV vergeleken met het levend/verzwakt poliovirus vaccin (OPV) dat
in de meeste andere landen wordt gebruikt. Verder werd ook de afweer na een
natuurlijke poliovirus infectie onderzocht.
Bescherming tegen poliomyelitis (kinderverlamming) wordt afgelezen aan de
aanwezigheid van poliovirus neutralizerende antistoffen in het bloed die het virus
onschadelijk maken. Deze antistoffen worden bepaald met behulp van een standaard
virus-neutralisatietest. Nadelen van deze test zijn echter o.a. de lange duur, en het
visueel moeten screenen van de uitslagen. Deze eigenschappen maken deze test erg
arbeidsintensief en onhandig om grote hoeveelheden te testen. Bovendien moet in de
neutralisatietest gebruik gemaakt worden van levend poliovirus. Pogingen om
eenvoudigere testen op te zetten hebben tot nu toe gefaald omdat met deze testen geen
onderscheid kon worden gemaakt tussen poliovirus neutraliserende en niet
neutraliserende antistoffen. Alleen de neutraliserende antistoffen zijn van invloed op
de bescherming tegen verlammingen veroorzaakt door poliovirus.
Met een nieuw opgezette Poliovirus Binding Inhibition test, afgekort PoBI (zie
hoofdstuk 2) is gebleken dat de resultaten van deze test sterk overeenkomen met de
standaard virus-neutralisatietest. De PoBI test is met name geschikt voor een snelle
screening van grote hoeveelheden sera zoals bijvoorbeeld nodig is voor het evalueren
van het Nederlandse vaccinatieprogramma. Bij dit soort studies wordt de
aanwezigheid bepaald van poliovirus immuniteit binnen de Nederlandse bevolking en
eventuele risicogroepen worden zo in kaart gebracht. Een belangrijk voordeel van de
PoBI test is dat niet langer gewerkt hoeft te worden met levend poliovirus. Dit is dus
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veel veiliger. Dit is met name belangrijk voor het uitroeiings programma waarbij in de
toekomst het werken met levend poliovirus zal worden ontmoedigd of zelfs verboden.
Onder deze omstandigheden is de PoBI test een uitstekend alternatief voor de nu nog
veel toegepaste neutralisatie test.
Binding van de eerder beproken virus-neutraliserende antistoffen vinden plaats op
heel specifieke plaatsen op de buitenkant van het poliovirusdeeltje. Binding van deze
antistoffen voorkomt o.a. aanhechting van het virus aan gevoelige cellen zodat deze
niet meer kunnen worden geinfecteerd. Drie belangrijke bindingsplaatsen betrokken
bij de poliovirus neutralisatie zijn geidentificeerd op het oppervlak van het
poliovirusdeeltje. In het maag-darmkanaal waar het poliovirus normaal gesproken het
lichaam binnenkomt bevindt zich het enzym trypsine, dat de eigenschap heeft de
buitenkant van het poliovirus te kunnen veranderen dat bepaalde virus-neutraliserende
antistoffen niet meer werken. Bij contact met poliovirus via het maag-darmkanaal
zouden er dus problemen op kunnen treden omdat na vaccinatie met IPV niet de juiste
antistoffen zijn aangemaakt en het virus tijdelijk kan ontsnappen aan het
immuunsysteem. Dit komt omdat personen die gevaccineerd worden met
geinactiveerd virus het vaccin rechtstreeks in de spieren krijgen geinjecteerd en het
virus dus niet in aanraking komt met trypsine uit het maag-darmkanaal. Hierdoor
maakt het immuunsysteem alleen maar antistoffen die een intact virusdeeltje kunnen
neutraliseren.
Om dit mogelijke gevaar te bestuderen hebben we testen opgezet om antistoffen tegen
de verschillende plaatsen op het virusdeeltje apart te kunnen meten (zie hoofdstuk 3).
Zowel in het bloed van personen, gevaccineerd met IPV als personen die in contact
zijn geweest met poliovirus via het maag-darmkanaal (OPV en patienten) werden
naast antistoffen tegen de trypsine gevoelige plaatsen ook antistoffen gevonden tegen
de ongevoelige plaatsen. Er is dus geen reden om aan te nemen dat IPV vaccinatie een
mindere bescherming geeft tegen poliovirus dat via het maag-darmkanaal
binnenkomt.
Er zijn dus geen benoemenswaardige verschillen tussen de antistof response na
vaccinatie met geinactiveerd virus of met levend verzwakt virus. In beide gevallen
werkt de vaccinatie uitstekend tegen het voorkomen van verlammingen omdat het
poliovirus voordat het het centrale zenuwstelsel kan bereiken al wordt uitgeschakeld.
Het is echter nog niet duidelijk of IPV vaccinatie ook een bijdrage kan leveren aan
bescherming tegen een (her-)infectie met poliovirus. Dit komt omdat IPV in de
spieren wordt geinjecteerd en door deze route waarschijnlijk geen effect heeft op de
locale afweer in het maag-darmkanaal. Bescherming op de slijmvliezen van het maag-
darmkanaal is zo belangrijk omdat daar het poliovirus normaal gesproken het eerste
binnenkomt. Wij hebben testen opgezet om polio antistoffen op slijmvliezen (zg IgA)
te kunnen meten (zie hoofdstuk 4). Na een natuurlijke infectie ontwikkelen alle
patienten dit type antistof in hun bloed. IgA gericht tegen poliovirus werd ook vaker
teruggevonden bij OPV gevaccineerden (zijn geinfecteerd geweest via het maag-
darmkanaal). Wij vonden een leeftijdsafhankelijke toename van poliovirus-specifiek
IgA in het bloed van de Nederlandse bevolking. Deze resultaten kunnen alleen goed
verklaard worden door een natuurlijke blootstelling met levend poliovirus uit de
omgeving en kan niet verklaard worden door de IPV vaccinatie zelf. Ook bleek dat na
een her-vaccinatie van personen die in het verleden op natuurlijke wijze geinfecteerd
waren met poliovirus een sterke toename hadden van polio-specifiek IgA in het bloed.
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Deze resultaten ondersteunen de hypothese dat IPV alleen IgA kan induceren na een
eerder contact met poliovirus via het maag-darmkanaal.
Om verder uit te zoeken of IPV een bijdrage kan leveren aan afweer op de
slijmvliezen werd een groep van volwassen IPV en OPV gevaccineerden opnieuw
gevaccineerd met IPV (zie hoofdstuk 5). IgA antistoffen werden zowel bepaald in het
bloed als in het speeksel. In de IPV gevaccineerde groep werd in geen enkel geval
IgA terug gevonden op de slijmvliezen. Deze resultaten laten zien dat vaccinatie met
alleen IPV niet voldoende is om mucosale immuniteit te induceren. Dit betekent een
mogelijke mindere bescherming tegen een herinfectie met poliovirus en dat deze
groep eventueel kan bijdrage aan een stille circulatie van polio in Nederland. Her-
vaccinatie met IPV gaf echter in de eerder OPV gevaccineerde groep een heel sterke
IgA respons tezien, zowel in het bloed als op de slijmvliezen. Veel van de IgA
producerende cellen uit het bloed bleken ook onderweg te zijn naar het maag-
darmkanaal om daar voor de nodige bescherming te zorgen. IPV bleek dus een
uitstekende stimultor te zijn van het mucosale immuun systeem mits men eerder met
poliovirus in aanraking was geweest via het maag- darmkanaal. Deze bevinding geeft
aan dat voor een juiste interpretatie van resultaten uit het verleden, waarin mucosal
immuniteit na IPV vaccinatie wordt beschreven, waarschijnlijk te maken heeft met
eerdere natuurlijke blootstelling aan poliovirus.
Poliomyelitis is klinisch heel moeilijk te onderscheiden van andere oorzaken van
acuut optredende verlammingen. In veel gevallen wordt door artsen niet meteen
gedacht aan een poliovirus-infectie als een mogelijke oorzaak, zeker niet in landen
waar een hoge vaccinatiegraad is bereikt zoals in Nederland. Hierdoor wordt in veel
gevallen de patienten niet of veel te laat virologisch onderzocht. Toch is het uitsluiten
van poliovirus als mogelijke oorzaak van belang voor het eradicatie programma,
omdat deze cijfers een beeld kunnen geven in hoevere poliomyelitis is uitgeroeid en
wanneer men voorzichtig kan gaan denken aan het stoppen met vaccineren. In
hoofdstuk 6 beschrijven we verschillende methoden die kunnen bijdragen aan de
diagnostiek van poliovirusinfecties. Met name door het bepalen van antistoffen, die
alleen worden aangemaakt bij een eerste contact met poliovirus en in de acute fase (zg
IgM), kan gedurende een langere periode na de eerste ziektedag nog betrouwbaar
uitsluitsel geven worden over een mogelijke poliovirus infectie.
Ondanks de nog aanwezige problemen van het eradicatie programma van polio
worden er toch grote vorderingen gemaakt. Maar voordat we kunnen spreken over een
poliovrije wereld moeten we er ons eerst van verzekerd hebben dat poliovirus nergens
meer kan voorkomen, ook niet bij de gevaccineerde bevolking. Poliovirusinfecties bij
gevaccineerden zijn heel moeilijk op te sporen omdat deze personen nooit ziek
worden van een infectie en er dus geen enkele reden is om deze personen virologisch
te onderzoeken. Vandaar dat de afwezigheid van klinische gevallen van
kinderverlamming in een gevaccineerde populatie nooit voldoende bewijs is voor de
afwezigheid van poliovirus. Nieuwe eenvoudige methoden om eventuele
poliovirusinfecties bij de gevaccineerde bevolking te kunnen vaststellen zullen
moeten worden ontwikkeld om deze vraag te kunnen beantwoorden.
Wij vonden echter bij jonge IPV gevaccineerde kinderen geen mucosale antistoffen
wat dus hoogst waarschijnlijk betekent dat deze kinderen nooit in aanraking zijn
geweest met het poliovirus. Deze resultaten zijn een duidelijke aanwijzing dat de
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jonge generatie polio-vrij is gebleven ondanks dat vaccinatie met IPV niet leidt tot een
mucosale afweer. Dit geeft aan dat we op de goede weg zijn naar de volledige
uitroeiing van polio in Nederland. De polioepidemieen in Nederland zullen dan




AFP acute flaccid paralysis
BSA bovine serum albumin
CNS central nervous system
CSF cerebrospinal fluid
CPE cytopathic effect
eIPV enhanced inactivated poliovaccine
ELISA enzyme-linked immunosorbent assay
ELISPOT enzyme-linked immunospot assay









PCR polymerase chain reaction
PBS phosphate-buffered saline
pNPP p-Nitrophenyl Phosphate
PoBI Poliovirus binding inhibition assay
RIVM Rijksinstituut voor de Volksgezondheid en het Milieu (National Institute of Public
Health and the Environment)
rpm rotation per minute
SC secretory component
sIgA secretory immunoglobulin A
SVM Stichting voor de Volksgezondheid en het Milieu (Foundation for the advancement of
Public Health and Environment)
TCID tissue culture infective dose
TMB tetramethylbenzidine
VAPP vaccine-associated paralytic poliomyelitis
VP virion protein
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